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 Research cannot generate truth, only evidence and conclusions. 
 
  
ABSTRACT 
Autoimmunity towards components of the central nervous system (CNS) is a driving factor of 
nerve demyelination in Multiple Sclerosis (MS). The etiology of autoimmunity in MS 
pathogenesis remains elusive, but a combination of genetic predisposition and environmental 
triggers is theorized to initiate this complex disease. 
Oxidative stress and lipid peroxidation represent insults to tissue homeostasis and are 
associated with inflammation and tissue damage. Reactive molecules associated with these 
processes covalently modify proteins forming post-translational modifications (PTMs). These 
PTMs alter the topology and biochemical properties of carrier proteins, which potentially 
impinges on their recognition by the immune system. Immunological self-tolerance to rare 
determinants derived from PTM antigen is poorly established, which is a theoretical basis for 
the development of autoimmunity. 
Myelin Oligodendrocyte Glycoprotein (MOG) is a minor surface antigen expressed 
specifically on myelinating oligodendrocytes in the CNS but is a major target in CNS 
autoimmunity. 
Study I addresses the innate recognition and immunological consequences of MOG modified 
by malondialdehyde (MDA), a reactive product of lipid peroxidation. MOG-MDA is 
phagocytosed efficiently and selectively by macrophages via Scavenger Receptor A (SRA), 
most efficiently by homeostatic M2-type macrophages. Higher uptake of MOG-MDA 
enhances the proliferation of autoreactive T cells in vitro but induces equal severity in 
experimental autoimmune encephalomyelitis (EAE), the animal model of MS. Taken together 
the results imply primarily homeostatic clearance of MDA-modified antigen by macrophages, 
but also a presentation to previously licensed T cells for screening purposes. The phenotype 
and activation state of the macrophage may influence the response to MDA-modified antigen. 
Furthermore, the results imply a dissociation of effects mediated by MDA adducts as opposed 
to the soluble chemical. 
Study II introduces a useful in silico molecular modeling plugin tool for various PTMs that 
can be used to address related research questions and predictions. 
Study III combines approaches from Study I+II to address the immunology of MOG nitration, 
a modification related to oxidative stress and inflammation. A combination of molecular 
modeling, bioinformatics, in vitro and in vivo data supports the conclusion that nitration denies 
the presentation of the dominant MGO35-55 epitope by H2-IA
b due to nitration of the critical 
anchoring residue Tyrosine-40 rendering it incompatible with the p1 pocket. Nitration thus 
represents a potential silencing effect depending on the major histocompatibility complex 
(MHC) haplotype. Accordingly, nitrated MOG is poorly encephalitogenic in H2b C57BL/6 
mice, but fully encephalitogenic in H2q DBA1 mice. 
Study IV functionally and phenotypically fully characterizes two fundamentally different sets 
of bone marrow-derived dendritic cells (BMDCs) generated in vitro by alternative protocols. 
These BMDCs resemble certain populations of antigen presenting cells in vivo and can be used 
to study immunological principles related to immunology. 
Collectively, this thesis provides both innovative tools to approach and novel insights relating 
to the impact of post-translational modifications on autoimmunity.  
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1 INTRODUCTION 
1.1 MULTIPLE SCLEROSIS 
1.1.1 THE BASICS OF MULTIPLE SCLEROSIS 
Multiple Sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) with 
recurring autoimmune inflammation directed towards myelin components [1]. MS has an 
increasing gender bias with up to a 3.5:1 female:male ratio [2]. Scandinavia has the worldwide 
highest prevalence of MS, almost 2:1000 [3-5], although the overall prevalence is lower at 
approximately 1:100 000 [2]. 
Patients typically experience bouts of disease involving a range of neurological symptoms2 [3] 
that vary in severity and can be clinically evaluated according to the ordinal Expanded 
Disability Status Scale (EDSS) [6]. MS is a chronic disease currently lacking a definitive cure. 
Accordingly, MS can be subdivided into relapsing-remitting (RRMS), secondary progressive 
(SPMS), or primary progressive (PPMS) courses [7]. The majority of patients presents with 
RRMS and can be effectively treated for decades, although relapses are not prevented entirely 
(cf. Figure 1). The increasing disability over time is a serious quality of life issue for patients, 
and a socio-economic healthcare problem. 
 
1.1.2 THE PATHOLOGY AND MECHANISMS UNDERLYING MS 
1.1.2.1 Myelin 
In order to understand MS we need to understand myelin. Briefly, myelin is the insulation of 
nerve axons that allows for salutatory3 conduction of signals mediated by depolarizing action 
potentials. The myelin insulation organizes various sodium channels to intermitting 
unmyelinated sections known as nodes of Ranvier. Signal transduction ‘jumps’ along these 
nodes, instead of moving along the entire axon at a significantly slower rate [8-10]. 
Importantly, axons do not necessarily require myelination to function independently4, although 
myelination is required for fast signal transduction. Accordingly, myelinated axons grow 
highly dependent on trophic support by the myelinating cell, especially since myelination 
isolates axon stretches from access to the interstitial space [8]. Axon myelination is performed 
by Oligodendrocytes in the CNS, and by Schwann cells in the periphery [9]. Apart from tissue 
                                                 
2 Among others: numbness, vision disturbances, pain, depression, urogenital problems, spasticity, fatigue, 
cognitive impairment, paralysis and ataxia. 
3  Latin: saltare: jump 
4 As evident by low conductivity, unmyelinated C fibers 
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specificity, there are notable differences between these cell types: Schwann cells only 
myelinate one stretch of a single axon, while Oligodendrocytes myelinate multiple axons [9]. 
Importantly, there are several Oligodendrocyte-specific proteins, including PLP, MBP, CNP 
and MOG (Figure 2). 
The biology of myelination is extremely fascinating and too complex to be discussed here in 
full detail (cf. [8-10] for reviews). I recommend reading references [8, 9], which contain 
brilliant illustrations. The bottom line is that the entire myelin machinery is devoted to 
metabolically support the axon, which in turn becomes highly efficient, but also entirely 
dependent on the performance of the myelinating cell. 
 
Figure 1: Schematic course of Multiple Sclerosis 
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1.1.2.2 Demyelination and MS pathology 
Tus far we have established the importance of trophic support for axons by myelinating 
oligodendrocytes [8]. In MS this dependence becomes disturbed as myelin becomes focally 
destroyed by the misguided immune system. Hallmarks of MS pathology include 
inflammation, temporally and focally dynamic de- and remyelination, complement deposition, 
compromised blood-brain barrier integrity, tertiary lymphatic follicles in the CNS, brain 
atrophy, axonal damage and neurodegeneration [1, 11]. 
Though demyelination is in principle reversible it presents a major insult to the homeostasis of 
the CNS, which is one factor underlying the relapsing-remitting phenotype of MS [12]. Even 
axonal damage can be temporary [13], but the level of stress may vary depending on whether 
the axon has access to interstitial space for autarkic support or whether it is being ‘suffocated’ 
by malfunctional myelin. Proficient remyelination is required for a return to homeostasis, but 
it is the irreversible degree of neurodegeneration that correlates with disability in MS [1, 11]. 
The pathogenesis of MS is very complex (reviewed in [1]). Notably, most MS mechanisms are 
being unraveled based on translation of the EAE animal model. Relevant mechanisms and the 
EAE model will be discussed further below.  
  
The triggering events initiating Multiple Sclerosis (MS) precede clinical presentation by an 
unknown period of time, presumably several years. Preclinical autoimmune inflammation and 
lesion formation possibly occur long before noticeable manifestation, with variability in the 
individual’s threshold. Clinically evident relapsing-remitting MS is further characterized by bouts 
of disease and recovery with variable frequency and intensity. This course may last decades with 
the available disease modifying drugs that reduce the relapse rate. Over time, however, 
neurological deficits and brain atrophy increase and are not fully resolved. 
In progressive MS, which is as yet driven by not fully elucidated alternative mechanisms, the 
classical treatment options do not yield benefit. Neurological deficits persist, most likely due to 
irreversible axon damage and neurodegeneration as the CNS fails to compensate for 
demyelination and the lack of trophic support. 
It is debated whether secondary and primary progressive MS share the same late stage 
mechanisms but differ in the time of clinical manifestation. The figure was adapted from (Olsson, 
2014), after an original conception by Mohsen Khademi. 
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Figure 2: Myelin structure 
 
 
1.1.2.3 T cells as main mediators of disease in MS 
A ground laying genome-wide association study for MS has confirmed a role for inflammatory 
cell-mediated disease [14]. The initiation of MS itself is incompletely understood [15], but the 
prerequisite is that autoreactive lymphocytes escape deletion by central tolerance mechanisms. 
In fact, MS is largely driven by autoreactive T cells [16], also evident by the effect of treatments 
targeting T cells [17] (discussed further blow). Taken together, this indicates underlying defects 
in the maintenance of tolerance mechanisms [18].  
A plethora of studies has since unraveled mechanistic differences of Th1 and Th17 cells in 
CNS inflammation, along with the relative importance of various cytokines [19, 20]. In order 
for T cells to be licensed they rely on MHC-restricted antigen being presented by various 
activated APCs (reviewed in [21]). In this context, antigen processing and presentation are vital 
The inlet magnifies a half section of a myelinated CNS axon near the node of Ranvier. 
Selected proteins and their subcellular locations are depicted. The figure was adapted 
from Mayer et al. (2012). 
 
CNP: 2',3'-cyclic-nucleotide 3'-phosphodiesterase (3rd most abundant myelin protein) 
MAG: Myelin Associated Glycoprotein 
MOG: Myelin Oligodendrocyte Glycoprotein 
MBP: Myelin Basic Protein (2nd most abundant myelin protein) 
Nrf: Neurofascin 
PLP: Myelin proteolipid protein (most abundant myelin protein) 
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[22], as are effects such as bystander activation. It has recently been suggested that the lungs 
are possibly an organ where T cells may acquire a CNS-inflammatory phenotype [23]. The 
current understanding is that T cells, which recognize various myelin-specific epitopes, 
transgress into the CNS and induce inflammation. The demyelination itself appears to be 
orchestrated by T cells but is specifically mediated by infiltrating GM-CSF-driven monocytes 
[24, 25], whereas CNS-resident microglia clear debris [26]. Notably, in human MS there is a 
significant contribution by CD8+ T cells, which is poorly represented in most EAE models [27].  
Furthermore, epitope spreading to new determinants can occur over the course of CNS 
inflammation [28, 29]. This epitope spreading is relevant for the propagation of autoimmune 
inflammation and induction of relapses [12]. Taken together, both in patients and EAE, there 
is ample evidence for individual T cell responses against myelin antigens such as PLP, MBP 
and MOG [1]. 
 
1.1.2.4 B cells and autoantibodies in MS 
Although MS is perceived to be mainly T cell mediated, B cells and antibodies contribute 
significantly to the pathology [30]. Tertiary lymphoid follicles and oligoclonal 
immunoglobulin bands inside the CNS are hallmarks of CNS inflammation in MS, and 
furthermore the CNS entertains a B cell fostering milieu [1, 30]. The relevance of B cells in 
MS is highlighted by the fact that several B cell-targeting treatment are effective in RRMS 
[30]. 
The contribution of B cells to MS is two-fold: first, B cells secrete pro-inflammatory cytokines 
such as IL-6 [31] and act as APCs independently of their capability to produce secreted 
antibodies [32]. Secondly, B cells and differentiated plasma cells are the producers of auto-
antibodies against various CNS antigens [30], including MOG [33], Neurofascin 155 [34] and 
possibly KIR4.1 [35]. 
The most-studied autoantigen in MS is MOG. This relates to the fact that MOG is a major 
antigen in myelin, despite being poorly represented (0.05% of myelin protein) [36] and its 
location in the outermost layer of myelin, as opposed to other myelin components (cf. Figure 
2). However, the anti-MOG seropositivity for MS is low (<4%), and more prevalent in pediatric 
demyelinating diseases such as ADEM5 (~27%) (reviewed in [37]). Depending on the study, 
up to ~30% of MS patients tests positive for MOG antibodies [38] nonetheless, but there is 
significant heterogeneity in approaches and study populations [37]. The method and material 
used to test for autoantibodies notably have significant impact on the readout [33]. For instance, 
there is a significant amount of human antibodies that are not cross-reactive with rodent MOG, 
as tested with various MOG-expressing transfected cells [39]. Furthermore, MOG 
glycosylation [40] and conformation [41] are factors that potentially affect its recognition by 
                                                 
5 acute disseminated encephalomyelitis (ADEM) 
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antibodies. Accordingly, cell-based assays are suggested to be most effective [37]. The 
heterogeneity of MS patients in terms of antibody responses, and the lack universal testing 
methods, assay cutoffs, the possibility of intrathecal local production and lastly the fact that 
even healthy controls are detected with MOG antibodies severely limit the usefulness of MOG 
as a diagnostic marker [33, 37, 42]. However, MOG seropositivity in MS patients possibly 
offers a stratification principle, e.g. for B cell targeting therapies [42]. 
A novel axonal autoantigen was recently reported with a subgroup of MS patients having 
antibodies towards the potassium channel KIR4.1 [43, 44]6. Such KIR4.1 antibodies were 
subsequently implicated in the pathology of MS [35] and childhood acquired demyelinating 
disease [45]. However, several failures to independently confirm KIR4.1 as an autoantigen 
have contributed to a highly controversial state of the subject [46]7 [47]. Possibly technical 
approaches are to blame for these discrepancies: first, the detection relies on peptide ELISAs 
in many experiments, one of the sequences reportedly requiring chemical ‘stapling’ in order to 
be a conformational epitope8. Secondly, with regard to the endogenous protein, that lab 
proposes that neuron-specific glycosylation of KIR4.1 may be required for antibody 
recognition9. Personally I am skeptical towards both these claims as they are somewhat 
contradicting. Furthermore peptide ELISAs for conformational epitopes are technically highly 
questionable. Much credibility is given to the group’s report that they could identify MS 
patients in blinded samples using KIR4.1 reactivity as a marker10. Whether KIR4.1 as an MS 
autoantigen withstands long-term scrutiny will have to be evaluated. 
1.1.2.5 Progressive MS 
There are essentially two forms of progressive MS: secondary or primary progressive.11 SPMS 
can be regarded as the inevitable continuation of RRMS when remissions cease to occur and 
treatments lose their effect. Conversely, PPMS variants are regarded as aggressive forms and 
typically lack signs of improvement. 
The pathological hallmarks of progressive MS are shared with RRMS but are often more 
pronounced [11]. The current hypothesis implies that progressive MS is driven by additional 
pathological mechanisms [11]. These include compartmentalized CNS inflammation, 
oxidative damage (enhanced by extracellular iron deposition), mitochondrial dysfunction, 
diffuse white matter injury, glutamate-induced excitotoxicity and failing trophic support, all of 
which lastly contribute to axonal degeneration and irreversible neuronal death [8, 11, 48, 49]. 
                                                 
6 ATP-dependent inwardly rectifying potassium channel Kir4.1; (K = potassium, ir = inward rectifying) 
7 This report failed to detect significant differences, despite collaborative approaches with the lab originally 
reporting Kir4.1 as an autoantigen. Many additional labs criticized the validity of KIR4.1 as autoantigen in MS 
(ISNI conference in Mainz, 2014). 
8 ISNI conference in Mainz, 2014; personal communication with Rajneesh Srivastava (first author of the original 
KIR4.1 report) 
9 As above, with poster and abstract 
10 Bernhard Hemmer (last author of the original KIR4.1 report), ISNI 2014 talk 
11 There are more variants distinguished clinically that I decided to omit 
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1.1.3 RISK FACTORS 
While the exact etiology of MS is still elusive it is unrealistic that a single cause will ever be 
identified because MS is a complex heterogeneous disease [50] – a syndrome with many causes 
rather than a single disease entity. Though the interplay of various risk factors is poorly 
understood, it is commonly accepted that the cumulative stacking of individual risks beyond a 
certain threshold is responsible for initiating MS as a result of genetic predisposition and 
environmental triggers. 
1.1.3.1 Genetic risk factors 
The strongest genetic association with MS is the HLA region [51]. Specific haplotypes are 
associated with increased risk of MS12, in particular the class II HLA-DRB1*15:01 allele with 
an odds ratio of 3.92 (8.30 if homozygous) [51]. 
In contrast to the Rheumatoid Arthritis (RA) field, in which HLA risk haplotypes associated to 
RA and their respective (modified) antigens are mostly resolved [52], the presented epitopes in 
MS are still elusive. Identifying potential target antigens may go a long way in understanding 
more about the pathogenesis of MS. Conversely there is the notion that certain HLA alleles 
may exert antigen-independent effects. It is also puzzling that there are numerous class I alleles 
that display a protective effect against MS13, notably HLA-A*02:01. How this relates to the 
risk and pathogenesis of MS remains unclear, but a connection to viral clearance or deletion of 
autoreactive CD8+ T cells appears plausible. 
Remaining non-HLA genes are more complex. The large scale GWAS study [14]14 revealed a 
long list of candidate MS risk genes, both previously known and novel ones. The majority of 
those strongly supported an involvement of the immune system in MS, in particular T cells. 
Importantly, the individual odds ratios of these non-HLA genes are comparatively low, ranging 
from just over one to ~1.6 at the most. In parallel, animal congenic strains have been useful in 
identifying loci that regulate EAE susceptibility [53]. 
A future development already in progress will be to elucidate the role of identified candidate 
genes in MS risk and pathogenesis, but also to investigate potential interactions and the 
combined risk of multiple parameters, both genetic and environmental [54]. 
1.1.3.2 Environmental risk factors 
The concept of MS as a complex disease predates the recent genetic studies and several 
environmental factors have been implied in the risk of MS [55].  
                                                 
12 Class II risk alleles: HLA-DRB1*15:01, HLA-DRB1*13:03,HLA-DRB1*03:01, HLA-DRB1*08:01, HLA-
DQB1*03:02; Positive interactions: HLA-DQA1*01:01 with HLA-DRB1*15:01; HLA-DQB1*03:01 with HLA-
DQB1*03:02 (Moutsianas et al., 2015) 
13 Class I protective alleles: HLA-A*02:01, HLA-B*44:02, HLA-B*38:01, HLA-B*55:01 (Moutsianas et al., 
2015) 
14 Make sure to check the supplementary information of this article for a detailed list of candidate genes. 
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Major environmental factors associated with MS include smoking [56], lack of vitamin D and 
infection with Epstein-Barr virus, particularly adult infectious mononucleosis [21][15, 57]. 
Other confirmed risk factors for MS include obesity [58] and night shift work for young adults 
[59]. Dysregulation of N-glycosylation has been proposed as a mechanism potentially driving 
MS [14] and sequence identity of MOG R101DHSYQEE108 and Chlamydia was suggested as 
molecular mimicry [60]15. However, the latter two concepts have not been validated or 
experimentally confirmed. 
The lack of vitamin D has been associated with elevated MS risk based on a latitudinal 
distribution of MS: prevalence is more common with distance from the equator, even within 
Sweden [5]. The latitudinal distribution of MS was attributed to lack of 1,25-dihydroxyvitamin 
D, precursors of which are generated in the skin in response to sunlight [15, 55, 61]. Notably, 
it has been demonstrated that this effect takes effect in early life [62, 63]. Multiple experimental 
studies have since demonstrated effects of vitamin D on immune system elements including 
DCs, macrophages and T cells [61], particularly Th17 cells [64, 65], and amelioration of EAE 
[66]. Another line of evidence is seasonal variation of relapses, most likely connected to the 
expression of immune-related genes [67]. MS patient self-reportedly tend to fair better with 
sunlight exposure and milder climate, but also with physical exercise16. Among other studies, 
the exercise aspect has been addressed in the EAE model with positive implications: mice with 
voluntary access to a running wheel exhibited milder EAE symptoms [68]. On the other hand 
it is unclear to which degree genetic effects influence the geographical distribution of MS. 
Furthermore, UV radiation has effects that are vitamin D-independent [69]. 
Cigarette smoking is by far the largest, and potentially avoidable, risk factor not only for MS, 
but for autoimmune diseases in general [56]. The mechanisms through which smoking drives 
autoimmunity are still elusive, but likely relate to depleted antioxidant responses and chronic 
immune activation in the lungs, recently demonstrated as being very relevant to T cell licensing 
[23]. Post-translational modifications promoted by reactive components potentially contribute 
to inflammation, but detailed studies will be required to address these notions in the context of 
EAE. Interestingly, epidemiological studies have revealed that oral tobacco ‘snus’ has 
protective effects on MS [70]17. This implies nicotine as a candidate immunomodulatory 
mediator [71]. Importantly, there is positive interaction of the MS risk for smoking and risk 
HLA haplotypes [72]. This interaction is highly relevant in the context of genetic predisposition 
and environmental triggers conveying a stacking overall risk of developing MS. 
                                                 
15 This sequence happens to localize to the DA rat (1AV1 haplotype) MOG epitope 91-108, although this could 
possibly be random; the RDHSYQEE sequence is very short and reminds more of a CD8/ MHC class 1 epitope. 
Chlamydia spp. are intracellular parasites. 
16 Patient meeting during courses. 
17 Prof. T. Olsson from our Neuroimmunology Unit frequently takes the opportunity to highlight this research 
result to the entertainment of the audience 
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1.1.4 TREATMENT OF MS 
For a more complete and detailed perspective on the treatment of MS I refer to a recent review 
by F. Piehl [17], a clinician from our department.  
Current first-line treatments mostly employ IFNβ (1a: Avonex, Rebif; Plegridy18 [7, 73]; 1b: 
Betaseron/betaferson, Extavia,) or glatiramer acetate (Copaxone19). IFNβ has multiple effects 
on T cells and neuronal survival (reviewed in [74]), and has been reported to inhibit the 
differentiation of Th17 cells [75]. Interestingly serum IL7 has been suggested as a marker for 
treatment benefit with IFNβ [76]. The mechanism of glatiramer acetate is elusive, but it may 
affect antigen presentation and has been reported to promote Tregs. 
Infusions of monoclonal antibodies have the benefit of being highly specific for the target they 
were raised against and, unlike small molecules, do not carry the same risk of various metabolic 
or off-target side-effects. However, antibodies may not have the same permeability and their 
exogenous nature carries a risk of patients developing intolerance to the antibody. The current 
trend is therefore to strive towards humanized, or entirely human antibodies to maximize their 
safety profile. A major healthcare challenge is that these antibody preparations are extremely 
expensive. 
Natalizumab20 is successfully used in the treatment of MS under the trade name Tysabri. Its 
target it the Integrin alpha-4, part of the VLA-421 complex on lymphocytes, which is important 
for their migration into CNS tissue. Although Tysabri is very effective in treating RRMS, a 
clinical problem is posed by the risk of developing progressive multifocal leukoencephalopathy 
(PML) as a result of opportunistic infection with JC virus22 which is no longer controlled by 
virus-specific T cells affected by treatment [17, 55]. This complication requires monitoring 
patients for JC virus and switching treatment regime, but also highlights the challenges arising 
from targeting immune mechanisms indiscriminately. 
Other antibodies for specific treatment, both existing and in development, are Rituximab23, 
Ocrelizumab24 and Ofatumumab25 (all anti-CD20 on B cells), Daclizumab26 (anti-CD25 on T 
cells) and Alemtuzumab27 (anti-CD52 on lymphocytes) [7, 17]. 
Fingolimod (Gilenya) is an orally-administered small molecule antagonist to sphingosine-1-
phosphate receptors (S1PRs) on lymphocytes and prevents the egression of T cells into the 
                                                 
18 A PEGylated version with longer half-life requiring fewer administrations 
19 A mixture of randomized oligomers of amino acids in MBP 
20 Tysabri, humanized monoclonal 
21 Very late antigen 4 
22 John Cunningham virus 
23 Rituxan, mouse/human chimeric monoclonal 
24 Pending tradename, humanized monoclonal 
25 Arzerra; pure human monoclonal,  
26 Zenapax, humanized monoclonal 
27 Lemtrada, humanized monoclonal; originally designed as a lymphoma treatment 
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circulation. Other oral drugs are Teriflunomide (Aubagio) that targets cell proliferation, and 
Laquinimod (Nerventra) that modulates NF-κB [17].  
An upcoming novel drug is dimethyl fumarate (DMF, BG-12, Tecfidera). Despite being 
successfully tested in clinical trials [77, 78] its mode of action is elusive, but one suggestion is 
that DMF activates the transcription factor Nrf2 and the cellular antioxidant response [17]. The 
activation of Nrf2 most likely can be attributed to the ability of DMF to undergo Michael 
additions [79] with primary amines, thus forming protein adducts that possibly deactivate 
Keap128, a negative regulator that sequesters Nrf2 in the cytoplasm and promotes its 
degradation. There are valid concerns related to the long term efficiency of DMF [80] and the 
fact that it possibly evokes severe allergic skin reactions [81]. I am bringing up the latter 
because it relates to protein adduction and MDA. 
My concluding perspective on existing treatments is that they target various immune 
mechanisms related to CNS inflammation. Based on the new mechanisms identified in 
preclinical models we may expect novel targets already being evaluated [7]. Importantly, there 
is the need to elucidate the mechanisms driving progressive MS and to identify potential 
interventions. Neuroprotection, myelin repair and oxidative balance are emerging aspects that 
will be of interest in this context [1, 48, 82]. Secondly, early diagnostic markers would be 
valuable to diagnose MS early and to start treatment early or possibly to prevent disease 
development to begin with. 
1.1.5 CONCLUDING REFLECTIONS ON MS 
In summary, there is ample evidence for MS being an inflammatory autoimmune disease 
entailing demyelination and neurodegeneration. While the etiology and mechanisms of MS are 
still elusive we begin to understand vital pieces of the puzzle. Future MS research will be 
dedicated to solving the outstanding questions and identifying the contribution of individual 
risk genes, environmental factors and their interplay. This may reveal new leads for potential 
interventions, especially with the aim of curing the cause and halting progression. 
Understanding the recognized heterogeneity among MS patients and disease courses will be 
vital in the quest for resolving disease mechanisms, but also for diagnosis and treatment 
stratification.  
 
  
                                                 
28 Kelch-like ECH-associated protein 1 
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1.2 MYELIN OLIGODENDROCYTE GLYCOPROTEIN 
1.2.1 THE MOG GENE 
Interestingly, the gene locus for Myelin Oligodendrocyte Glycoprotein (MOG) is located 
within the HLA region. The HLA region located on chromosome 6p in humans and on 
chromosome 17 for mice is otherwise well known for its abundance of genes related to the 
immune system, in particular the HLA genes involved in antigen presentation. However, MOG 
itself appears not to fall into that category. Importantly, the expression of MOG is restricted to 
the CNS in mature oligodendrocytes, late in their maturation process [36]. 
In the human genome the MOG gene spans around 17 kb and has 8 exons [83]. Notably these 
exons undergo complex alternative splicing in humans but not in rodents [84]. On a side note, 
complex alternative splicing in primates is in general believed to a major factor accounting for 
an elevated evolutionary complexity in the light of otherwise striking similarity between 
orthologous genes [85]. Conversely, alternative splicing has been suggested to be a factor 
contributing to the development of autoimmunity [86]. One underlying principle for the latter 
is a lack of immune tolerance as a consequence of targeted regions of autoantigens being 
encoded by exons that are not expressed during embryonic development or especially in the 
thymus mediating the deletion of autoreactive T cells. A prime example is that 
immunodominant epitopes of PLP map to a region that is absent in its shorter isoform (called 
DM20), which is the only variant expressed in the thymus unlike in mature oligodendrocytes 
[22, 86]. 
The current USCS genome browser assembly29 [87] lists 9 curated human MOG isoforms30 
and additional variants pending RefSeq validation can be accessed31. By comparison the mouse 
assembly32 features two variants, one with all exons and the other lacking exon 6. The rat 
assembly33 only lists one variant. The respective splice variants have been described in detail 
by Delarasse et al. [85], and I have included an adapted summary in Figure 3. Nonetheless, the 
splicing of MOG itself is considerably complex and the respective splice variants that affect 
mostly the C-terminal, intracellular domains of MOG and are discussed below. 
 
                                                 
29 Dec. 2013 (GRCh38/hg38) 
30 uniprot.org lists 9 curated isoforms and a total of 13 isoforms 
31 XM_005249139.2 for a transcript containing the ALU element, corresponding to a secreted variant of MOG 
32 Dec. 2011 (GRCm38/mm10) 
33 Mar. 2012 (RGSC 5.0/rn5) 
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1.2.2 THE MOG PROTEIN STRUCTURE 
1.2.2.1 MOG protein domains and features 
Discussing MOG gene architecture goes hand-in-hand with the corresponding protein 
structure. The exons are as follows: Exon 1 = signal peptide (removed during processing), Exon 
2 = extracellular IgV domain, exon 3= transmembrane domain, exons 4 & 5 = cytoplasmic 
regions, exon 6A/B = membrane associated region, exon 7 = linking region, exon 8A/B = tail 
region. Additionally, the so-called ALU element in intron 2 is considered a non-canonical 
alternative exon that encodes less-abundant, truncated and soluble versions of MOG. The 
individual domains are depicted in Figure 3. 
Importantly, the canonical and most abundant isoform of MOG, namely α1, corresponds to the 
rodent versions and consists of the extracellular domain (exons 1+2) followed by a single 
transmembrane domain (exon 3), a cytoplasmic stretch (exons 4+5), a membrane-associated 
region (exon 6) and a tail region (exons 7+8) [84, 88], cf. Figure 3.  
The MOG protein was originally discovered as a lectin-binding (i.e. glycosylated) protein 
[88]34 purified specifically from CNS tissue. MOG was further characterized by its lacking 
resemblance of known CNS proteins such as Myelin Basic Protein (MBP) and lastly defined 
as the target recognized by the monoclonal antibody 8-18C5 [89]. Of all historic alternative 
names Myelin Oligodendrocyte Glycoprotein (MOG) was established in recognition of the 
glycosylation, specific expression in oligodendrocytes and association to myelin [36]. 
 
1.2.2.2 The extracellular IgV domain of MOG 
Most research focus has addressed the conserved extracellular domain of MOG. The crystal 
structure of recombinant MOG has been resolved for rat MOG alone [PDB-ID: 1PKO] 
(1.45 Å) and as a complex of rat MOG with Fab fragments of the defining anti-MOG antibody 
8-18C5 [PDB-ID: 1PKQ] (3.0 Å) [60]. Furthermore, the crystal structure of recombinant 
mouse MOG has been resolved independently [PDB-ID: 1PY9] [90]. This extracellular domain 
of MOG belongs to the immunoglobulin V-set (IgV) as it is structurally related to the variable 
domain of antibodies [60, 90]. The IgV domain features the typical antiparallel β sheets, linked 
by a single disulfide bridge between the B and F sheets (cf. Figure 3). 
Intron 2 contains the so-called ALU element that can serve as a non-canonical exon with two 
possible splice variations both containing a stop codon, named ALU-10A or ALU-10B, 
respectively [84] (cf. Figure 3). Furthermore, transcription of variants containing the 2’ intron 
                                                 
34 It was later shown that some isoforms are not glycosylated and insensitive to the glycosidase 
Endo-H 
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region constitutes a third alternative stop codon, yielding the Ig-2’ transcript of MOG [84]. 
These three variants are considered to be secreted versions of MOG, consisting of essentially 
only the IgV domain, yet their biological role or relevance remain unknown. 
The IgV domain supposedly mediates interaction with putative ligands and thereby the function 
of MOG. Although the overall importance and exact function of MOG remains elusive, studies 
have proposed a range of potential functions including MOG being a homo-dimer and adhesion 
molecule [90], MOG regulating the classical complement pathway [91] or MOG being a 
receptor for Nerve growth factor (NGF) [92]. These functions will be discussed individually 
below. 
 
1.2.2.3 The cytoplasmic domains of MOG 
Very little is known about the function of the cytoplasmic domains of MOG, apart that the 
isoforms influence the cellular localization, to e.g. the surface or endoplasmic reticulum [88]. 
Especially in rodents, MOG is mainly regarded as a surface-expressed protein with a single 
transmembrane domain. Interestingly, exon 6A encodes a stretch of the membrane associated 
domain containing two cysteines C177 and C19835 that are hypothesized to either be 
palmitoylated and/or interact with membrane galactocerebroside (Gal-C), the latter being a 
specific glycosphingolipid marker for oligodendrocytes [36]. Palmitoylation and interaction 
with Gal-C would support that this domain interacts closely or alternatively is embedded into 
the cell membrane. Exon 6B is by contrast devoid of cysteines. Nonetheless, the functional 
consequences of cytoplasmic variations, potential interacting proteins and possibly signaling 
pathways associated to MOG are yet to be identified. In particular the existence and relevance 
of variants lacking the extracellular domain requires clarification.  
  
                                                 
35 Numbering according to processed MOG sequence 
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Figure 3: Myelin Oligodendrocyte Glycoprotein 
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1.2.3 STRUCTURAL SIMILARITY OF MOG TO THE B7 FAMILY AND BUTYROPHILINS 
The IgV domain of MOG has significant structural similarity to members of the B7 family such 
as CD80, CD86 and PD-1. CD80 and CD86 bind the activating CD28 receptor on T cells or 
the attenuating CTLA-4 on activated T cells. However, although the tertiary structure of the 
MOG IgV domain is strikingly similar to that of CD80, MOG does not feature the amino acid 
topology that would allow binding to either CD28 or CTLA-4. This statement is based on a 
series of structural alignments I performed using the crystal structures of MOG [PDB-ID: 
1PY9], CD28 [PDB-ID: 1YJD] and a complex of B7.1 (mouse CD80) and CTLA-4 [PDB-ID: 
1I8L] (data not shown).   
Furthermore, the MOG IgV domain shares structural similarity to domains of butyrophilin 
(BTN) family. Butyrophilins have diverse tissue-specific roles related to lipid secretion and 
metabolism. In particular, BTN1A1 has established roles in the mammary gland and is present 
in milk lipid droplets [93]. Other more ubiquitous functions relate to immunology: BTN1A1 
and BTN2A2 have been demonstrated to negatively regulate T cell activation and cytokine 
secretion [93]. However, MOG was used as a control in the study identifying a T cell regulatory 
role for BTN1A1 and BTN2A2 [93], but had no such effect. BTN3A (CD277) has a role in the 
A) Sequences and structure information for recombinant MOG: Top: sequences of 
recombinant mouse MOG (rmMOG), rat MOG (rrMOG) and human MOG (rhMOG); 
Lysines are indicated in bold blue, Tyrosines or Tryptophanes in bold red; selected 
epitopes in EAE and MS are indicated with orange bars, the MHC haplotype is 
indicated in brackets for the rodent strains. Bottom: The secondary structure and 
nomenclature, as adapted from (Clements et al., 2003): white = loops, red = α-helix, 
glue/green = proximal/distal β-sheet (cf. B). The connecting line between the B and F 
β-sheets indicates the disulfide bridge. 
B) 3D model of rmMOG from [PDB-ID: 1PY9] (Clements et al., 2003). The colors and 
nomenclature correspond to those in in A. 
C) The gene structure of MOG. Exons and ALU element = thick bars, introns = thin bars; 
Intron/exon lengths are indicative of size, but not to scale. The protein domains encoded 
by the corresponding exons are labeled as indicated. Exons 6 and 8 feature mutually 
exclusive A or B splicing alternatives. Adapted from (Delarasse et al., 2006). 
D) Simplified illustration of MOG proteins corresponding to the indicated splice variants. 
Note that the colors correspond to the exons in C). The predicted size [kDa] is displayed 
beneath the splice variant name. Additionally the cellular location is indicated for 
experimentally-studied variants (Boyle et al., 2007). Potential, natural post-
translational modifications (glycosylation, Palmitoylation; cf. Johns et al., 1999) are 
depicted as in the legend insert. Note that exon 6A contains modifiable cysteine 
residues (C177 and C198), whereas exon 6B does not (cf. Uniprot-ID: Q16653, α1 vs. 
α3). The membrane-associated region encoded by exon 6 is depicted as membrane-
embedded for exon 6A and cytoplasmic for exon 6B. 
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activation of γδ T cells [94], which is interesting given that γδ T cells may contribute to MS 
[95].  
Interestingly, the similarity of MOG to butyrophilins present in milk has inspired the hypothesis 
that dairy-containing diet may influence the risk or treatment of MS. Immunization of DA rats 
with BTN74-94 peptide or passive transfer of BTN74-94-specific T cells evoked meningeal and 
perivascular cell infiltrates in the CNS [96]. Conversely, high-dose i.v. treatment with BTN74-94 
peptide ameliorated EAE induced by MOG74-94-specific T cell transfer [96]. Another study 
reported antibody cross-reactivity between BTN and MOG in MS patients and suggested 
molecular mimicry as an underlying principle [97]. Regrettably this particular study is entirely 
based on antibody ELISA using peptide epitopes as opposed to folded protein. 
Highlighting the structural similarity of MOG to proteins that happen to have roles in 
immunology is misleading in a sense that it may prompt the assumption that MOG itself may 
have such a function. However, I should point out that the immunoglobulin superfamily has 
many members with functions not related to the immune system and that the name is mostly 
historical and relates to the structural features of antibodies, a.k.a. immunoglobulins. Similarity 
in tertiary structure alone does not allow the drawing of conclusions about function. 
 
1.2.4 THE PHYSIOLOGICAL FUNCTIONS OF MOG 
The function of MOG is either redundant or non-essential. Firstly, MOG appears relatively 
recently in evolution and can be found in mammals, but is absent in other vertebrae e.g. reptiles 
[36]. Secondly, MOG knockout mice display no physiological phenotype [98]. 
 
1.2.4.1 MOG as an adhesion molecule 
One proposed function for MOG is as an adhesion molecule for myelin compaction. First, 
MOG shares sequence homology with other adhesion molecules, namely the adenovirus 
receptor D1 domain (CAR), myelin protein zero (P0) and junctional adhesion molecule (JAM) 
[90]. Secondly, mouse MOG has the tendency to form dimers resistant to denaturing conditions 
in vitro [36, 90]. Dimerization of MOG is supported independently by biochemical evidence 
[36], Biacore measurements [90], as well as structural modeling of the MOG dimer [90]. 
However, what argues against MOG being an adhesion molecule is the fact that MOG 
represents a meagre 0.05% of myelin protein [36], making potential interactions statistically 
rare. Furthermore, even ectopic expression in cell lines did not induce cell clumping, in contrast 
to P0 [36]. Lastly, electron microscopy comparing myelin from wild type and MOG knockout 
mice did not reveal notable differences [98]. Nonetheless, the possibility that MOG serves as a 
minor adhesion molecule cannot be entirely excluded. 
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1.2.4.2 MOG as a potential regulator of complement component C1q 
Several studies conducted in the late 1990s implied a connection between myelin and the 
complement system (reviewed in [36]). Notably, Johns et al. reported MOG to bind C1q in a 
calcium-dependent manner and thereby to inhibit the classical complement pathway [91]. 
Frankly the implications for MS are intriguing. Complement deposition is a hallmark of MS 
pathology, triggering demyelination and affecting adaptive immunity [99], and it has been 
reported that complement component C3 primes microglia [100]. Convesely, complement 
fulfills a plethora of non-inflammatory housekeeping functions, e.g. the clearance of apoptotic 
cell debris, pruning of synapses in the CNS [101, 102] or regulation on Wnt signaling [103]. 
Accordingly, the reported interaction with MOG and negative regulation of C1q [91] 
potentially has considerable implications for the CNS and MS. 
 
1.2.4.3 Excursion: The discontinued MOG and C1q project 
Based on the above, I was naturally intrigued by the potential role of MOG and regulating C1q 
in the context of MS. To recapitulate the original publication [91] made a few major claims: 
1. MOG binds to C1q 
2. The binding of MOG and C1q is possibly Ca2+-dependent, (addition of EDTA 
decreased binding and addition of Ca2+ increased it) 
3. MOG inhibits the classical complement pathway (demonstrated in a complement-
dependent lysis assay of red blood cells) 
I initiated an entire project trying to reproduce the claim that MOG binds to C1q, possibly in a 
Ca2+-dependent manner. In continuation it would be a goal to further experimentally confirm 
this and to investigate the specific nature and functional consequences. To cut a long story 
short, despite suggestive initial data, the experiments did not support a specific, nor Ca2+-
dependent interaction of MOG and C1q, nor did pure MOG appear to regulate the classical 
pathway in vitro (data summarized in Figure 4). Instead the data raises question about the 
validity of the above claims. 
Initially, investigating the calcium dependence looked somewhat promising. The MOG55-73 
sequence displayed some partial matching to the canonical EF-hand motif for Ca2+ binding 
(Figure 4A), but there were clear deviations. A generated 3D model localized the putative site 
to a flexible loop region within MOG (Figure 4B) with possible implications on conformational 
changes. Importantly, the site localized closely to a ExRxR motif which was proposed in the 
original publication as the possible interaction site with C1q [91], but this site is localized at 
the base of the protein facing the cell membrane. The fact that none of the structural 
publications of MOG detected or implied Ca2+ binding also inspires healthy skepticism [60, 
90]. Regardless, experimental ELISAs did actually confirm binding of MOG to C1q (Figure 
4D), although the signal appears to be more indicative of the degree of MOG aggregation than 
specific interaction (cf. Figure 4E). In order to interpret the data one needs to know that 
production batch 9 contained some MOG multimers, while production batch 10 contained 
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fewer of these. Additionally, re-purification using size exclusion chromatography was applied 
to separate the monomeric and dimeric fractions (cf. Figure 4D). Monomeric protein clearly 
displayed reduced detection compared to aggregated protein. 
An additional question in this project was also whether PTMs would sterically interfere with 
C1q interaction and entail functional consequences. Alternatively, MDA adducts are reported 
to be recognized by certain complement components [104, 105]36 and to induce interaction 
with the carrier protein. A major technical problem was that MDA-modifications37 or 
nitration38 also promoted aggregation of MOG in vitro due to crosslinking, and thus influenced 
the ELISA readout. In fact, the binding of monomeric proteins (re-purified by SEC in some 
cases) was low and almost in the range of background. Addition of extra calcium or omission 
of calcium and the presence of EDTA did not notably increase or abolish binding as previously 
claimed [91]. Lastly, a functional complement lysis assay on human platelets did not show any 
functional consequence of MOG being present (Figure 4F). Taken together, this mostly 
negative data did not encourage continuation of the project. Corresponding to the above claims, 
I have listed some conclusions and open question of my own: 
1. The major determinant of ELISA reactivity appeared to be the presence of MOG 
aggregates. Is the binding in any way specific, or does C1q merely bind the aggregated 
and misfolded protein? If so, how was the quality of the MOG used in the original 
publication? 
2. There is no evidence for Ca2+ dependence. Did the original publication neglect artifacts 
induced by precipitation of insoluble CaHPO4, a common mistake when using calcium 
in combination with PBS-based buffers? 39 
3. Is there any specific function associated with the MOG54-73 region? 
Concerning this project there were not only technical difficulties and artifacts I became aware 
of but the overall construct of the project appeared artificial and questionable upon reflection. 
I decided anyhow to include the data in form of this excursion for two reasons: Firstly I wanted 
to challenge the claim that MOG actually specifically interacts with C1q. Secondly I intend to 
highlight that sustainable science requires awareness and thoroughness to allow the recognition 
of flaws and artifacts, as well as the necessity to report and discuss negative data. 
1.2.4.4 MOG as CNS-specific receptor for Nerve growth factor 
A more recent study has now revealed that MOG has a hitherto unknown function, namely to 
bind and sequester Nerve growth factor (NGF) [92]. This function fits to the CNS-specific 
expression of MOG. In particular, the thorough study by von Büdingen et al. [92] demonstrates 
MOG binding NGF (KD = 581 pM) and aberrant sprouting of TrkA
+ nerve fibers in MOG-/- 
                                                 
36 Potentially MDA adducts are recognized by C1q (Anna Blom, Lund University, personal communication); 
preliminary experiments. 
37 Possibly targeting K55 and/or K73 
38 Possibly affecting Y65 (we now know from Paper 3 that Y65 is poorly nitrated) 
39 CaHPO4 precipitates easily in solution when Ca2+ is added to PBS and may co-precipitate protein; the original 
publication added up to 5mM Ca2+, standard calcium-containing PBS formulations contain about 0.9mM. 
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mice. TrkA is an established neuronal NGF-binding receptor tyrosine kinase and is structurally 
related to MOG, yet more distantly compared to the B7 family. Notably, compared to TrkA 
MOG features a more extensive loop between the C’’ and D strands (residues 61-81), cf. Figure 
3, which corresponds to the region studied in connection to C1q. 
1.2.4.5 MOG and interaction with DC-SIGN 
MOG has been demonstrated to interact with the via C-type lectin DC-SIGN via fucosylated 
N-glycans on MOG [106]. Together with TLR4 activation this interaction decreased T cell 
proliferation via the secretion of IL-10 [106]. Conversely, the absence of myelin fucosylation 
promoted Th17 subsets [106]. These observations imply a tolerogenic role for MOG depending 
on its glycosylation. Interestingly, dysregulated N-glycosylation has been suggested as a 
pathogenic denominator in MS [14]. Importantly, there are notable differences in expression 
distribution between human DC-SIGN (associated to DCs) and its rodent variant DC-SIGNR1 
(associated among others to marginal zone macrophages). The tolerogenic signature of DC-
SIGN-expressing APCs in the context of glycosylation has been proposed as a therapeutic 
approach in autoimmunity [106]. 
1.2.5 MOG IN NARCOLEPSY 
A mutation in the MOG gene has been associated with inheritable narcolepsy [107]. This 
C398G mutation results in a non-synonymous S104C40 substitution in the MOG protein. The 
affected residue is located at the very tip of the MOG IgV domain just prior to the final β-sheet, 
a region known to interact with the 8-18C5 antibody [60]. As opposed to MS, however, there 
is no evidence for autoimmunity directed towards MOG in the affected narcolepsy patients 
[107]. Most likely the additional cysteine, as a result of the mutation, interferes in the proper 
structural folding of the IgV domain and produces non-functional protein. Nonetheless, the role 
of MOG in the context of narcolepsy remains elusive. 
Interest in autoimmune narcolepsy spiked after the link between increased cases and the 
Pandemrix™ vaccine41 was established, along with the strong association with HLA-
DQB1*0602. However, later studies attributed autoimmune narcolepsy to molecular mimicry 
and cross-reactive immune responses between influenza nucleoprotein and human 
hypocretin/orexin (reviewed in [108]), neuropeptides with established roles in regulating 
wakefulness and food intake. Interestingly, the familial narcolepsy associated with the MOG 
mutation is also associated with obesity in roughly 50% of the cases [107], but it is neither clear 
whether this is actually attributable to the mutation nor how it speculatively would be connected 
mechanistically.
                                                 
40 The original publication uses the numbering according to the full length precursor sequence, including the 
signaling peptide (29 residues). S133C corresponds to S104C in the processed version. 
41 H1N1 flu vaccination during 2009/2010 in Europe 
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Figure 4: The discontinued MOG and C1q project 
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A) A comparison of the MOG sequences to the canonical EF-hand motif for Ca2+ binding 
according to PROSITE (http://prosite.expasy.org/PS00018). Note that square brackets 
indicate allowed (required) choices while curly brackets indicate disallowed choices, 
‘x’ can represent any amino acid. The MOG sequences indicated in green match the 
canonical motif. However, the sequences fail to meet the criteria with P63 being a 
mismatch and G67R68T69 being additional inserts/mismatches. Notably, this region 
overlaps with the ExRxR motif proposed to resemble to the C1q binding motif in 
antibodies, as indicated(Johns et al., 1997) 
B) Based on the crystal structure of mouse MOG [PDB-ID: 1PY9] a hypothetical calcium 
ion was modeled into the center of potentially chelating amino acids (Glutamic acid, 
E or aspartic acid, D). Larger structural rearrangements as a result of conformational 
change were not taken into account. The E64xRxR68 sequence is colored red1. The 
proximal amino acids to the hypothetical calcium ion (grey, 1.85Å radius) are 
displayed as sticks with oxygens highlighted in red. Modeling the calcium in this 
position is highly suggestive of D56, D58 and E60 potentially chelating the ion, however, 
this would theoretically require the participation of the backbone oxygen of L50 as well 
as the oxygens of Q57 and Q61 in the chelation and most likely a change in 
conformation. 
C) Schematics for the ELISA setups of C1q-coatead MOG ELISA (left), or the inverted 
setup with MOG-coated C1q ELISA (right). 
D) C1q-coated MOG ELISA data from selected experiments. The controls indicate that 
there is some background with the antibody, which is possibly bound by C1q. Samples 
from production batch 9 indicate that there is interaction between MOG and C1q but 
that the detection is influenced heavily by the amount of non-monomeric, potentially 
misfolded, forms of MOG. Additional samples from batch 10 reveal not only batch 
variation (production batch 10 being purer and more monomeric), but also that 
increasing the calcium concentration or eliminating it in the presence of EDTA does 
not increase or eliminate the binding, respectively. MDA modification of MOG 
appeared to increase binding only due the promotion of multimer formation 
(crosslinking). Nitration also displayed ambiguous effects, also most likely related to 
the degree of multimer formation. The overall take-home messages from this data are 
that although C1q possibly binds MOG, or rather aggregates thereof, the interaction 
cannot be reliably assayed using this setup, and calcium does not appear to make any 
difference. 
E) Concept of MOG multimers negatively affecting the ELISA readout. 
F) Experimental data testing the ability of MOG to inhibit the classical complement 
pathway. Human platelets were prepared by labeling with calcein dye, then incubated 
in the presence of various proteins and antibodies directed to the platelets and serum. 
The platelets were subsequently stained and prepared for analysis by FACS. The 
FACS analysis demonstrated calcein release from lysing platelets in all samples with 
antibody (left), but the presence of highly pure monomeric MOG or BSA control did 
not prevent lysis. Similarly the presence of MOG did not prevent the platelets from 
being coated with C1q or C3. 
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1.2.6 MOG AS AN AUTOANTIGEN 
In the majority of MS-related studies MOG is a tool to induce EAE rather than a subject of 
research. The latter sadly factors into the reality that comparatively little is known about the 
physiological functions of MOG, apart from what has been suggested by the individual studies 
discussed above. 
1.2.6.1 MOG as an established MS autoantigen 
Quickly after its discovery the research focus shifted towards the role of MOG as an 
autoantigen in MS and translated as a means to induce EAE (reviewed in [109]). It was quickly 
established that immunization with MOG protein induced EAE [109]. Shortly after, the 
immunodominant peptide in C57BL/6 mice was mapped to MOG35-55 and the peptide EAE 
model was established [110]. Subsequently, the presentation and recognition of the MOG38-51 
core epitope were fine-mapped in functional experiments [111, 112] and it was established that 
MOG35-55 is presented by H2-IA
b, with W44 being the major TCR contact [113]. 
MOG knockout mice are immune to MOG-induced EAE and display milder EAE symptoms 
in myelin-induced EAE [98]. This implies that although MOG is a minor component of myelin 
it is a major autoantigen in CNS demyelination. 
In the context of the MOG gene structure I discussed the splicing of human MOG [84] and the 
potential implications for autoimmunity [86]. Notably, the extracellular domain of MOG is not 
changed by splicing, but a recent study in mice suggested an additional encephalitogenic 
epitope of MOG residing in the transmembrane region (residues 119–132) [114]. 
 
1.2.6.2 MOG epitopes 
A few of the major MOG epitopes in rodents and humans are depicted in Figure 3 (pg. 14). In 
rodent models the dominant epitopes are well characterized, e.g. MOG35-55 for mice with the 
H2b haplotype (e.g. C57BL/6) or MOG79-98 for H2
q mice (DBA1) [115]. Human MOG epitopes 
are unsurprisingly more heterogeneous and cover most of the MOG IGV domain [116, 117]. 
Structural evidence for the binding of specific MOG, or myelin epitopes in general, to any of 
the established risk HLAs is still lacking in MS research. However, the developments in the 
production of MHC tetramers as well as high throughput analytical methods may open new 
avenues. 
 
1.2.6.3 MOG antibodies 
The location of MOG in the outermost layer of myelin (cf. Figure 2, pg. 4) has always been the 
motivation to study MOG in the context of autoantibodies. In human MS the situation 
concerning MOG-specific antibodies is considerably complex, partly due to controversies in 
studies trying to establish a role for MOG autoantibodies in MS (reviewed in [37]). Notably, 
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the patient heterogeneity in MS could potentially be stratified according to antibody serology 
profiles. 
In rodents the antibody responses are reported to mainly recognize folded MOG [118]. This is 
consistent with reports suggesting that MOG antibodies are generally conformational [41], and 
the fact that the MOG-defining 8-18C5 antibody is also conformational [36]. The crystal 
structure of rat MOG in complex with 8-18C5 has been resolved and this revealed that the 
antibody recognizes stretches from apical regions in MOG [60]. 
Several studies in mice imply that MOG antibodies are expendable for CNS demyelination, 
but in certain cases they can exacerbate demyelination. Conversely, not all MOG antibodies 
are capable of driving pathology [37], which may be connected to recognition of 
conformational or linear epitopes [119]. Importantly, the APC function, not the antibody 
production, of MOG-specific B cells is now identified as a critical contributor to MS 
pathogenesis [32].  
The fact that there are several protective class I alleles associated with MS [51] suggest viral 
infection, or clearance thereof, as a potential factor in MS pathogenesis. Relating to that, MOG 
has been suggested to be an adhesion molecule for Rubella virus [120]. Notably, this further 
relates to intrathecal production of anti-rubella IgG in MS patients [30]. The latter may indicate 
putative bystander activation related to the virus. The WHO recommends to make Rubella 
vaccinations routine to prevent outbreaks and birth defects associated with the virus [121]. 
Sweden vaccinates all children using combination vaccines, but women may receive booster 
vaccinations in case antibody titers are tested low.42 However, to my knowledge there is no 
epidemiological evidence that would support a connection of Rubella vaccinations to MS in 
these women, although this question could easily be addressed using the registries. 
 
1.2.6.4 Propagation of demyelination in the CNS may require a secondary priming with 
endogenous MOG  
The original priming with MOG in adjuvant appears not to suffice for EAE induction alone. 
The literature provides several lines of evidence that the propagation of demyelination in the 
CNS may require a secondary priming with endogenous MOG. Initial evidence for this comes 
from the observation that EAE induced by either rat or human MOG is driven by different 
mechanisms [122]. This is attributed to the S42P substitution in human MOG, implying that 
the EAE induced with human MOG35-55 peptide relies on the induction of a secondary response 
to the rodent version. More recently it was demonstrated that the EAE driven by human MOG 
is B cell-dependent [32]. Arguably, immunization with human peptide is highly artificial. 
However, the antigen processing machinery requires the IFNγ-inducible lysosomal thiol 
                                                 
42 Rubella infections in Sweden have since been practically eradicated, apart from rare imported cases or outbreaks 
associated to anti-vaccine communities in Järna (2012); source: Folkhälsomyndigheten (Swedish health authority). 
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reductase (GILT) in order to release to MOG35-55 epitope [119]. GILT is the product of the MS 
risk gene IFI30 [54], and is required to reduce disulfide bonds in order for antigens to be 
processed. GILT-/- mice are susceptible to EAE induced with rat MOG, but react to MOG 
epitopes from non-globular intracellular regions mentioned above. Conversely, GILT-/- mice 
also display an abundance of plasma cells and pathogenic MOG antibodies [119], which is not 
surprising for mice that have a deficiency in unfolding antigen into linear epitopes. Importantly, 
and surprisingly, GILT-/- mice are essentially resistant to MOG35-55 peptide EAE [119], 
although one might expect the opposite. In other words, MOG35-55-primed GILT
-/- mice have 
an ongoing T cell response that fails to propagate in the CNS because that requires local antigen 
presentation of the MOG35-55 epitope. 
Taken together, these data collectively imply that A) the initial T cell response to MOG35-55 
only induces minimal CNS demyelination and relies on propagation in the CNS, and B) 
processing events of endogenous MOG are required to enable this propagation. In conclusion, 
re-stimulation of infiltrating T cells by local APC in the CNS is already recognized as an 
important factor [1]. 
 
1.2.7 CONCLUDING REFLECTIONS ON MOG 
In summary, it appears that MOG has evolved in a very unique fashion to fulfill a range of 
functions that contribute to the CNS microenvironment. Together these may impact the 
developing or inflamed CNS in various ways, and there is more to be learnt about MOG itself 
and its role in CNS homeostasis. The establishment of MOG as an autoantigen in MS and its 
subsequent use as a tool to evoke EAE may have diverted efforts to elucidate its function. 
However, the insights gained from years of research using the EAE model have greatly 
deepened our understanding of MS. 
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1.3 EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS 
Pre-clinical research that aims to dissect disease mechanisms prior to clinical presentation relies 
on reproducible models that mimic the pathology and relevant aspects of the human disease. 
For MS research, this is the EAE model, Experimental Autoimmune43 Encephalomyelitis. 
1.3.1 THE HISTORY OF EAE 
The concept of experimentally-induced CNS inflammation originated in the mid 1920s 
(reviewed in [123]). Cornerstone observations relate to CNS inflammation induced by 
exposure to CNS extracts, most notably non-human primates during the elucidation of 
encephalitogenic complications with a rabies vaccine contaminated with myelin components 
(reviewed in [123]). Later, the use of Freund’s adjuvant44 enabled researchers to significantly 
boost immune responses and thus to induce EAE with a standardized single immunization 
(reviewed in [123]). Since then EAE has been induced in numerous species including mice, 
rats, rabbits and non-human primates in order to study immune mechanisms related to CNS 
inflammation.  
1.3.2 THE EAE MODEL 
1.3.2.1 Active EAE 
In essence the active EAE model boils down to immunizing animals with CNS antigen 
emulsified in adjuvant. The detailed aspects of this are reviewed in the literature [27, 124]. 
There obviously are many factors to tweak in the process of EAE induction. First, different 
animal species and strains react differently to the same immunization protocol. These 
differences reach as far as strains of the same background being either resistant or susceptible 
to EAE depending on the MHC haplotype [115, 125] or on individual non-MHC gene loci 
[126]. 
Secondly, the choice of antigen is critical. Pioneer studies used whole myelin extracts as 
antigen, but those inherently have significant variability in their composition. Recombinant or 
purified proteins and synthetic peptides thereof, i.e. defined antigens, are therefore currently 
the primary choices for EAE induction. Notably, the combination of a specific strain and 
antigen evokes variable disease courses that can be relapsing-remitting, chronic or progressive 
[27]. The disease course is furthermore influenced by the antigen dose and strength of the 
adjuvant, higher doses and stronger priming promoting EAE severity. EAE typically presents 
                                                 
43 Earlier studies refer to EAE as Experimental Allergic Encephalomyelitis, owning to the fact that the autoimmune 
aspect was unclear at the time. 
44 Incomplete Freund’s Adjuvant (IFA): 85% (v/v) paraffin oil, 15% (v/v) mannide monooleate; Complete 
Freund’s adjuvant (CFA): IFA + heat-killed mycobacterium tuberculosis (500-2000 µg/mL in final emulsion). 
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with a progressively ascending paralysis of tail and limbs and is monitored using an ordinal 
scale. 
 
1.3.2.2 Pertussis toxin 
In certain strains of mice the successful induction of EAE symptoms requires the 
intraperitoneal co-administration of ~200 ng pertussis toxin (PTx) on days 0 and 2. The 
requirement for Ptx administration relates to genetic susceptibility: for instance the C57BL/6 
strain requires PTx, whereas the DBA1 strain does not [115]45. The precise effects of PTx are 
incompletely understood but include genotype-dependent bystander activation [127], skewing 
of CD4+ T cells towards the encephalitogenic Th17 phenotype [128] and transient breakdown 
of BBB integrity with structural aberrations of organelles in microvascular endothelial cells 
[129]. Conversely, repetitive administration of PTx prior to immunization was reported to 
promote regulatory T cells and to counteract the development of EAE [130]. Furthermore, PTx-
induced BBB permeability is transient (~24h) [129], whereas EAE symptoms do not develop 
prior to ~10 days after immunization46. 
 
1.3.2.3 Passive EAE 
In contrast to active EAE, passive EAE does not involve immunizing the animal with antigen 
emulsion but rather involves T cell transfer [124, 131]. The passive EAE model itself was 
originally developed to demonstrate T cells being the pivotal mediators of disease in EAE 
[132]. For passive EAE the transferred T cells derive from actively immunized donor animals 
and are typically propagated in vitro by rounds of stimulation with the particular antigen and 
IL-2 [124, 131]. Furthermore, the Th subset of CD4+ T cells can be skewed by addition of the 
required cytokines such as IL-12 for Th1, or IL-6 and IL-23 for the Th17 subset [65, 131].  
A recent study suggests that transferred T cells acquire a migratory phenotype after initially 
homing to the lungs [23]. These licensed T cells transgress into the CNS and induce 
demyelination, evoking EAE symptoms that are often monophasic [124, 131]. Importantly, the 
Th subtype influences the location of inflammation, Th17 cells driving inflammation in the 
brain parenchyma and evoking ‘atypical’ EAE symptoms [20, 133, 134]. ‘Atypical’ EAE 
symptoms are characterized by unsteady gait, ataxia, and disturbances in axial and rotary 
orientation, often lacking the ascending paralysis that is typical for classical EAE. 
 
                                                 
45 DBA1 mice also require less CFA (~50-100 µg) and lower protein doses (<25 µg). 
46 i.e. 8 days after the last PTx administration. 
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1.3.3 2D2 MICE 
A extremely useful resource in assessing MOG-specific proliferation are 2D2 mice [135] which 
were developed on a C57BL/6 background and are transgenic for TCR chains recognizing 
MOG35-55 (Vα3.2 and Vβ11), derived from a MOG35-55 -reactive T cell clone [135]. Using 
functional studies the fine reactivity was later mapped to the core MOG38-51 epitope [111] 
which is presented by H2-IAb [113]. 2D2 mice are very useful in experimental research because 
they are a source of T cells with pre-defined reactivity towards MOG. Importantly, 2D2 mice 
allow bypassing of immunization of wild type mice and generating polyclonal T cell lines, 
although this approach may still be necessary depending on the research question. 
Notably, 2D2 mice are not the only MOG-specific TCR transgenic mice. Mendel et al., 
developed the so-called 13A strain (TCR Vα2/Vβ4) using essentially the same approach [136]. 
However, the A13 strain is resistant to active EAE, and T cell transfer of Th1 activated A13 T 
cells does not induce EAE in wild type mice [136]. Furthermore, A13 T cells secrete IL-4 and 
undergo apoptosis when stimulated with MOG35-55 and IL-12 [136]. Taken together, it appears 
remarkable that these strains exhibit such notably divergent phenotypes despite the only 
apparent difference between them being the transgenic TCRs. 
 
1.3.4 OTHER MODELS OF CNS AUTOIMMUNITY AND DEMYELINATION 
There is a range of uncommonly used spontaneous models for CNS infiltration, most of which 
rely on removal of regulatory T cells (e.g. by thymectomy) or ectopic expression of cytokines 
(reviewed in [137]). Other models of CNS demyelination include Japanese macaques [138] 
and Theiler’s virus induced demyelination [124]. Furthermore, there are additional chemical 
models [27] and genetically engineered mice [139, 140] that address demyelination and CNS 
infiltration [141]. 
While there are several transgenic mice with TCRs specific for particular myelin antigens 
[137], the incidence of spontaneous EAE is mostly low. For instance, less than 4% of the widely 
used 2D2 mice develop spontaneous EAE symptoms [135] although 30% present with optic 
neuritis. The fact that 2D2 mice do not develop EAE despite having transgenic T cells is 
enigmatic with respect to how difficult it can actually be to break tolerance. More recently, 
however, it has been demonstrated that transgenic mice with both 2D2 TCR and MOG-specific 
B cells have up to 78% spontaneous EAE incidence [32, 142]47. 
A recent study reports a novel model of immune-mediated CNS demyelination [143] in which 
administration of tamoxifen to transgenic mice induces oligodendrocyte death. Treated mice 
develop a late-onset disease characterized by motoric disturbances, the presence of MOG-
                                                 
47 0% in either MOG-specific B cells or T cells alone; 55% with both 2D2 TCR and MOG-specific B cells deficient 
in antibody secretion; 78% with both 2D2 and MOG-specific B cells able to secrete antibodies. 
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reactive T cells, secondary demyelination and CNS infiltration [143], but appear to lack the 
limb paralysis typical for EAE. This phenotype thus possibly resembles the disability and 
chronicity of early MS better than does the EAE model. Whether oligodendrocyte death elicits 
CNS autoimmunity has been controversial in earlier studies which focused on earlier time 
points [139, 140]. 
 
1.3.5 TRANSLATIONAL LIMITS OF THE EAE MODEL 
The EAE model is widely used in MS research and has been instrumental in identifying several 
mechanisms relevant to CNS autoimmunity [27]. Especially the use of various knockout mice, 
notably cell type-restricted knockouts, offers immense potential into addressing the relevance 
of particular targets [19, 54]. Among many others these models have highlighted the 
importance of T cell-derived GM-CSF [25] for inflammatory CCR2+ myeloid cells [24] for 
mediating demyelination as opposed to IFNγ [144] or IL-12p35 [145]. The EAE model also 
offers options to address environmental factors such as the microbiome [146] and diet [147, 
148]. 
Although the EAE model is instrumental in understanding CNS inflammation, it fails to fully 
mimic the complexity of human MS. Compared to MS as a heterogeneous syndrome EAE is 
inherently a controlled, yet very harsh and highly artificial model [1]. Active EAE has an 
inherent CD4+ T cell bias owing to the use of adjuvants [1, 27]. Furthermore, the location of 
lesions and the chronicity aspect of MS are poorly reflected in the EAE model [1, 141]. 
Monitoring demyelination vs. axonal degeneration can easily be inaccurate [149] and there is 
especially a lack of models resembling mechanisms related to progressive MS. The EAE model 
itself is very susceptible to treatment interventions, environmental factors and technical 
variation [146, 149]. Lastly, mice are not humans and there are notable differences in the 
respective immune responses. These differences impinge on both mechanisms and treatments 
identified using EAE. For instance, even though TNF has been implicated to drive EAE, anti-
TNF treatment, although successfully used in the therapy of RA, turned out to be detrimental 
in clinical trials against human MS [150]. 
Taken together, these and other limitations highlight the importance of critical assessments 
when drawing conclusions about clinical MS based on observations in EAE. Unless 
experiments are performed with good preparation and execution, randomization and blinding, 
they bear a significant risk for technical or subjective bias. Furthermore, awareness of potential 
limitations is a caveat for sustainable research performance. 
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1.4 POST-TRANSLATIONAL MODIFICATIONS 
Post-translational modifications (PTMs) are discussed in the introductions of the respective 
studies (I-III) and I consider it redundant to discuss these in more detail in the frame of the 
thesis. Instead I decided to focus the frame discussion more strongly on malondialdehyde 
(MDA) as it relates most to my research (especially Study I) and allows me to discuss details 
in a way that may not be possible in standard publications. Here I will very briefly discuss some 
of the concepts of PTMs, but otherwise refer to existing reviews [151, 152]. 
1.4.1 POST-TRANSLATIONAL MODIFICATIONS IN HOMEOSTASIS 
PTMs are covalent chemical modifications of amino acids that occur in proteins after synthesis 
[153, 154] and they vastly increase the variety of amino acids in proteins. The majority of 
PTMs occurs naturally and is mediated specifically by enzymes in order to (reversibly) regulate 
cellular signaling or metabolic processes. The best example is phosphorylation in signaling 
cascades being regulated by kinases and phosphatases. 
Conversely, the majority of non-enzymatic modifications are associated to disturbance to 
cellular homeostasis, but are normally taken care of. There are many examples for these 
different modification, but I refer to Study II for additional details. 
Importantly, many PTMs occur naturally and constantly in the body. My favorite example is 
the conversion of asparagine to iso-aspartate [153, 155]: during the conversion the protein 
backbone is linked instead to the side chain and introduces irregularities. Repair of iso-aspartate 
is repaired by the enzyme Protein L-isoaspartyl methyltransferase (PIMT). Deficiencies in 
PIMT are embryonically lethal in knockout mice that display accumulation of iso-aspartate 
residues, especially in the brain, and severe seizures [156, 157]. This examples highlights both 
how common PTM are and how relevant their repair is [158, 159]. 
1.4.2 MECHANISTIC LINKS OF PTMS IN AUTOIMMUNITY 
1.4.2.1 A brief outline of the theory of PTMs in autoimmunity 
Mechanisms of PTMs in autoimmunity have been previously reviewed [151, 152]. Here, I will 
simply go over them to introduce some terminology. The major underlying concept of PTMs 
in autoimmunity is that they impact protein recognition or processing by introducing novel 
epitopes, called neoepitopes. If the epitope contains a PTM, it is called an altered peptide ligand 
(APL). Conversely, if the epitope is released by altered protein processing events it is referred 
to as cryptic epitope. The theory of PTMs in autoimmunity assumes that neoepitopes are absent 
during negative selection of potentially autoreactive T cells in the thymus. These autoreactive 
T cells, having escaped central tolerance mechanisms, are the basis for adaptive autoimmunity.  
Consider that we are following an antigen from the point it becomes modified until it evokes 
an immune response. The modified antigen might resemble a protein the immune system 
recognizes as foreign ‘non-self’ or a pathogen due to similarities in topology or sequence. This 
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is referred to as molecular mimicry [160] and implies cross-reactivity of antibodies or T cells, 
with possible bystander activation during an ongoing infection.  
Modification of the antigen possibly entails innate recognition by scavenger receptors [161] 
and enhanced uptake into antigen presenting cells (APCs). This active mode of receptor-
mediated phagocytosis, as opposed to more passive modes of uptake, is highly effective and 
possibly activates cellular signaling pathways and thereby the APC. Activated APCs possibly 
contribute to the inflammatory microenvironment by their secretion of cytokines and 
expression of surface molecules. The critical steps for induction of adaptive autoimmunity are 
antigen processing and antigen presentation. A mentioned above the PTM may interfere with 
processing events, e.g. by saving a cryptic epitope from destructive processing [162], or 
changing the processing cascade entirely [163]. Alternatively, the epitope can contain the PTM 
and be an APL. This possibly enables epitope spreading to new determinants of the same 
protein, or a new target. The generated epitopes compete for binding to major 
histocompatibility complexes (MHC), the epitopes with highest affinity to a given MHC 
molecule being more likely to be presented [52].48 Lastly, all above events culminate in the 
recognition of a presented antigen by an autoreactive T cell and its activation. This brief recap 
may be slightly over-simplistic and fails to fully elucidate the complexity of the theory of PTMs 
in autoimmunity or explain examples in detail, but the purpose is to give an impression. 
 
1.4.3 PTMS IN MS 
The best-established involvement of PTMs in autoimmunity is citrullination in the Rheumatoid 
Arthritis (RA) field [52, 164], possibly also the related carbamylation [165, 166]. Conversely, 
in MS a potential involvement of PTMs is currently not conclusively established. Existing 
studies have addressed the immunogenicity of citrullinated MBP, which is rather complex as 
MBP itself in naturally citrullinated multiple times [167, 168]. There is furthermore evidence 
of epitope spreading to citrullinated antigens in EAE [169]. Another compelling example is 
that the MBPAc1-11 epitope requires N-terminal acetylation in order to be presented by I-A
u and 
induce EAE [170]. 
Furthermore, the contribution of oxidative stress and particularly lipid peroxidation were 
implied in the pathogenesis of MS [171-173]. Lipid peroxidation in MS [172, 173] and 
potential PTMS associated to oligodendrocyte death [174] therefore warrant researching the 
mechanisms in relation to MS pathogenesis. This has been a major factor behind Studies I-III 
and is discussed separately in their respective introductions. In the next chapter I will focus on 
introducing the background to lipid peroxidation and MDA modification. 
  
                                                 
48 This is well established for citrullinated APLs and their presentation by risk haplotypes in Rheumatoid Arthritis. 
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1.5 MALONDIALDEHYDE 
1.5.1 LIPID PEROXIDATION 
1.5.1.1 Lipid peroxidation gives rise to reactive aldehydes 
The major cause for the generation of MDA in vivo is lipid peroxidation [175, 176], in 
particular of poly-unsaturated fatty acids such as membrane arachidonic acid (AA) and 
docosahexaenoic acid (reviewed in [175]). Lipid peroxidation can be mediated in a 
comparatively controlled manner by enzymes with peroxidase activity for various synthetic or 
metabolic pathways (reviewed in [175]). Conversely, uncontrolled lipid peroxidation is 
considered a pathophysiological process driven by ROS [175-177] or RNS [178]. Apart from 
exogenous sources, ROS derived from enzymes including iNOS and NOX may contribute to 
this process [179].  
Lipid peroxidation as a separate subject field is very complex and reviewed elsewhere [177]. 
Importantly, several pathways have been described, though which downstream processes 
initiated by lipid peroxidation yield highly reactive aldehyde compounds including 4HNE [176, 
180] and MDA [176, 177, 181, 182]. Reaction products of MDA and 4HNE with biomolecules 
belong to a category collectively referred to as advanced lipoxidation end products (ALEs) 
[183]. Both MDA and 4HNE have been studied extensively as biomarkers of oxidative stress 
[184] and are implicated in the pathology of various diseases.  
A second major source of MDA is its generation as a byproduct in the synthesis pathway of 
thromboxane A2 (TXA2), although this is technically enzymatic lipid peroxidation. In the 
synthesis process MDA can be released from prostaglandin H2 which is in turn generated from 
arachidonic acid via cyclooxygenases (COX1/2) [185]. A schematic for this particular source 
is described in [181], but mechanistically the decomposition step releasing MDA corresponds 
to that depicted in Figure 5 (pg. 32) [176, 177]. 
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Figure 5: Schematic MDA generation by lipid peroxidation 
 
 
 
 
1.5.1.2 Antioxidant scavenging counteracting lipid peroxidation 
Lipid peroxidation is driven by free radicals. Accordingly, antioxidant defense mechanisms 
are highly relevant to limit the occurrence and extend of lipid peroxidation [186]. The most 
notable radical-scavenging antioxidants in relation to lipid peroxidation are α-Tocopherol 
(vitamin E) and linoleate [187], but other known antioxidants such as thioredoxin or 
glutathione are possibly also relevant [184, 188]. Importantly, radical-scavenging activity is 
essential in limiting the potentially detrimental consequences of ongoing lipid peroxidation 
[182, 186]. 
In relation to antioxidants it should be noted that factors that generally deplete the antioxidant 
capacity accordingly increase the risk of pathological processes being initiated by free radicals. 
This simplified schematic depicts the 
generation of MDA by lipid peroxidation. 
 
The initiating step is lipid peroxidation, i.e. 
the attachment of peroxide to the poly 
unsaturated fatty acid (PUFA) chain of a 
lipid. This lipid peroxidation can be 
initiated by ROS, or enzymes with 
peroxidase activity. 
 
The peroxidized lipid subsequently 
undergoes two steps of internal cyclization, 
first internally forming an endoperoxide, 
secondly forming a 5 carbon ring. 
Rearrangements within the lipid radical 
further entails additional peroxidation until 
scavenging of a hydrogen atom occurs. 
 
The resulting bicyclic endoperoxide can be 
a precursor for isoprostanes, thromboxanes 
and leukotrienes in enzymatic synthesis 
pathways, but readily decomposes to 
release MDA. 
 
Adapted from (Nam, 2011). 
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The latter agrees with smoking being a major risk factor for autoimmune diseases in general 
[56] and the increase of MDA-derived metabolites in urine in smokers [175]. Furthermore, 
aldehydes in cigarette smoke have been independently reported to react with MDA to form 
advanced reaction products [189, 190], and I will further discuss these below. 
Lastly, although technically not a radical-scavenger, the established COX2 inhibitor aspirin 
has been demonstrated to reduce both TXA2 and MDA[191], the latter often being used as 
readout for TXA2 synthesis [192]. This relates to the synthesis of TXA2 being driven by 
COX1/2 and generating MDA as a byproduct. 
 
1.5.1.3 Other sources of MDA 
Urine excretion products of MDA are influenced by thyroid hormones [193], diet [194], 
physical exercise, and smoking [175]. Apart from lipid peroxidation as the main source it has 
been suggested that MDA is generated by ionizing irradiation of carbohydrates [195], oxidation 
of the polyamine spermine [196] and UV radiation [197], in particular UV radiation of the lipid 
squalene [198]. Interestingly, squalene occurs naturally inside cells, but is also used in adjuvant 
formulations such as MF59 or AS03 [199]. Squalene by itself, however, does not elicit immune 
responses [200] and is used as dietary supplement and in cosmetics. Micelle formation is likely 
the critical step in conveying adjuvant properties of the mixture. 
 
1.5.2 MDA CHEMISTRY 
1.5.2.1 Generating MDA in vitro 
MDA is highly reactive and is not stable in its pure form. The standard method to generate 
MDA freshly for laboratory purposes is therefore through acid hydrolysis of 1,1,3,3-
tetramethoxypropane [201], which is depicted in Figure 6A (pg. 36). Similar to other aldehydes 
MDA is suggested to be more stable as its enol form, also called β-hydoxy-Acrolein, especially 
at low pH [202].  
 
1.5.2.2 Simple MDA reactions with primary amines 
MDA is a bifunctional aldehyde and is highly reactive. As aldehydes undergo condensation 
reactions with primary amines, it is not surprising that the initial reports of MDA adducts 
reported the Nε amines of lysines to be the main target of MDA [203]. Likewise, MDA also 
reacts with the primary amine of any amino acid N-terminus [204]. The latter has special 
relevance for the formation of Nα MDA adducts of phosphatidyl -serine in membrane lipids 
[205].  
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There has been some debate about the nature of simple MDA adducts [203]. The reaction of 
an aldehyde with an amine normally yields a Schiff base, i.e. an imine with a double bond at 
the nitrogen. However, since MDA is tautomeric it has been suggested that instead the 
enamine-al variant is the major adduct, featuring the double bond between the MDA carbons 
and an aldehyde as functional group (cf. Figure 6, pg.36) [203]. Besides lysine, other amino 
acids, namely arginine, glutamine and histidine, were reported to be modified by MDA [204]. 
However, the latter remains to be verified, as the chemical nature of the corresponding 
functional groups does not support modification by MDA. 
The imine bond formed between MDA and primary amines is in principle reversible by 
hydrolysis and is possibly pH dependent [206]. The reversibility has implications for the 
stability and half-life of simple MDA adducts in carrier proteins potentially acting as reservoirs. 
The availability of primary amines can be assayed using the TNBS assay [207], whereas 
detection of MDA adduct is performed using biochemical assays with adduct-reactive 
antibodies [208] or by Mass Spectrometry [209]. 
Lysine has a pKa of 10.67 and is expected to be protonated and positively charged at 
physiologic pH. Conversely, the evidence from various publications suggests that proteins 
modified by MDA become more net negatively charged (cf. Study I). The chemical reasoning 
is that both the Schiff base (imine) or alternatively the enamine do not favor the nitrogen being 
charged. Hence it is reasonable that the nitrogen becomes deprotonated in the process. 
 
1.5.2.3 Generation of advanced MDA adducts: FAAB, MAA and others 
The fact that MDA features two reactive aldehyde groups complicates its reaction spectrum 
significantly. Along with the notion that simple MDA adduct may not be stable it has become 
apparent that MDA-modified proteins display features that simple MDA adducts do not 
explain, namely increased spectrophotometric absorbance and the development of color49. 
Accordingly, advanced MDA reaction products were reported in the literature. These include 
the Malondialdehyde-Acetaldehyde adduct (MAA) [203, 210, 211], the FAAB50 adduct [210], 
as well as various crosslinks [203, 211, 212]. Reaction schemes for selected MDA-dependent 
adducts are depicted in Figure 6 (pg.36).  
The most studied advanced MDA adduct is MAA, which is formed by the reaction two units 
of MDA and a third aldehyde, in this case acetaldehyde, with a primary amine. This reaction 
forms a dihydropyridine (DHP) ring at the amine that cannot be hydrolyzed. The increased 
                                                 
49 These were among the observation I initially came across when working with MDA. The Nanodrop-based 
determinations of protein concentration would be unusable and grossly overestimate the yield, due to increased 
absorbance. Samples would also develop pale yellow colorations. 
50 FAAB: 2-formyl-3-(alkylamino)butanal; This adduct has been reported, but never convincingly demonstrated 
to be of any significant importance. 
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stability is relevant as many studies attribute observations to the MAA adduct rather than the 
MDA simple adduct.51 The exogenous addition of acetaldehyde to the reaction promotes the 
formation of MAA adducts [213]. However, the addition of acetaldehyde is not required as 
MDA itself releases acetaldehyde during decomposition, a step that is rate-limiting [214]. 
MAA adducts are thus generated in vitro even in the absence of the addition of acetaldehyde, 
but the yield is lower52 [213]. An alternative MAA reaction mechanism involving conversion 
of the FAAB adduct has been proposed [215]. Importantly, MAA adducts are reported to form 
in vivo [210] with potential implications of alcohol oxidation to aldehyde. 
Alcohol is oxidized in vivo by alcohol-dehydrogenases to acetaldehyde, transported via the 
blood and exhaled via the lungs, as acetaldehyde that is extremely volatile. Historically, 
acetaldehyde has been used by the police to test drivers for alcohol consumption using 
exhalation tests, but is modernly detected using spectrophotometry. Interestingly, the reaction 
mechanism of MAA links alcohol consumption, smoking and the lung microenvironment. The 
lungs have been demonstrated to be relevant for T cell licensing [23] and either acetaldehyde 
or aldehydes in cigarette smoke [189, 190] have been demonstrated to react to advanced MDA 
adducts. 
  
                                                 
51 The reasoning behind attributing observations to the MAA adduct often relates to elevated recognition of 
modified proteins by MDA-reactive antibodies. This could imply both more effective generation, but also 
prolonges stability. 
52 See also: Supplementary material of Study I 
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Figure 6: MDA chemistry 
 
 
  37 
 
 
 
 
 
  
A) In vitro generation of MDA from 1,1,3,3-tetramethoxypropane by acid hydrolysis. The acid 
catalyzes the hydrolysis of the methoxy ethers to methanol. Complete hydrolysis yields 
MDA. MDA is tautomeric with its enol form (aka β-hydroxy-acrolein) suggested to be 
favored. 
B) The reaction of lysine with MDA generates an MDA adduct on the primary amine 
presumably by forming a Schiff base (imine). However, it is suggested that the final adduct 
of MDA tautomerizes to an enamine-al. This adduction of MDA to lysine is in principle 
reversible by hydrolysis and may be pH-dependent. The keto-enol tautomerism is 
highlighted to illustrate conformational challenges associated to Study II, flexible rotations 
are indicated by arrows. Notably, the aldehyde in imine-al or enamine-al adducts have the 
capacity to form crosslinks with other amines by the same reaction. 
C) This scheme combines the formation of the MAA adduct by two different mechanisms. 
Pathway 1: The upper path illustrates a simplified version of the mechanism proposed by 
Slatter et al. (1998) involving essentially a serial reaction of two units of MDA (red) and an 
aldehyde (blue) to form the MAA adduct dihydropyridine ring. Note that the ring-closing 
aldehyde could essentially be any aldehyde, including a third unit of MDA. 
Pathway 2: The lower pathway put forward by Tuma et al. (2001) instead proposes that the 
aldehyde reacts first with the amine followed by MDA to form the FAAB adduct. This 
FAAB adduct is then supposedly released in a reaction with a different amine and another 
unit of MDA, finally also yielding the MAA adduct. The asterisk indicates a chiral center 
for the FAAB adduct. 
Crosslinks: The carbaldehyde groups of the MAA adduct can condensate with additional 
primary amines to form crosslinks. Similar to the simple MDA adducts in B, these 
principally be hydrolyzed and are thus reversible. The advanced reactions of the EDHDC 
adduct formed by three units of MDA also has the possibility of reacting further with 
additional crosslinks. However, if the reaction involves a fourth unit of MDA, as indicated, 
then the crosslink becomes irreversible and forms the lipofuscin-like crosslink adduct 
reported by Itakura et al. (1996). All four adducts on the right half have fluorescent 
properties. 
 
Square brackets indicate transitional non-existing intermediates. 
FAAB: 2-formyl-3-(alkylamino)butanal 
MAA: Malondialdehyde-acetaldehyde adduct 
MDHDC: 4-methyl-2,6-dihydopyridine-3,5-dicarbaldehyde 
EDHDC: 4-ethenol-2,6-dihydopyridine-3,5-dicarbaldehyde 
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1.5.2.4 Problems: MDA in vitro production, crosslinks, oligomerization, artifacts 
Despite being widely used, the in vitro production of MDA-modified proteins does not 
resemble physiological conditions [216], a fact that warrants criticism, in particular concerning: 
 
1) Artificial, uncontrollable reaction conditions and adduct heterogeneity 
An issue is the abundance of MDA for in vitro preparations being artificially high. One may 
criticize that the applied concentrations may not resemble those generated during lipid 
peroxidation. This may not be an issue if the aim was merely to achieve a homogenous 
modification, but the ensuing problem is the reactivity of MDA. Various potential MDA-
derivatives were discussed in the preceding section, and apart from providing acetaldehyde to 
enforce DHP ring closure and MAA adducts one has relatively poor control over the reaction 
mechanism as a whole (cf Figure 6, pg.36), and among others MDA inevitably produces 
crosslinks [203, 211, 212].53 
 
2) Incomplete hydrolysis.  
Additional issues with MDA relate to incomplete hydrolysis during in vitro production and its 
ability to oligomerize. There is no guarantee that the hydrolysis of TMP as parental compound 
for MDA is complete, thus giving rise to artificial aldehydes that result in a much wider 
spectrum of adducts than anticipated. 
 
3) MDA oligomerization. 
At the concentrations used in vitro, and in the absence of amines, MDA immediately starts to 
oligomerize [217, 218], and giving rise to a multitude of condensation products and turning 
gradually from pale yellow to dark red. Pioneer studies on MDA already characterized the 
divergent properties of the condensation products and warned of the potential pitfalls of 
studying effects related to those rather than to MDA [219, 220]. 
 
4) Insufficient dialysis.  
This problem is probably the most relevant one, especially in terms of distinguishing the effects 
mediated by MDA protein adducts as opposed to those of soluble MDA. Dialysis is the method 
of choice to clean up the adduction reaction. Two main factors determine the dialysis 
efficiency: buffer excess and the number of dialysis rounds. Importantly, excess dialysis buffer 
only determines the relative exchange, e.g. ~1:1000, while the number of rounds increments 
the efficiency exponentially, i.e. ~1:1000n. Importantly, MDA itself has toxic and mutagenic 
effects at doses of 100 nM or above [205] (discussed below), so the question arises whether 
certain effects are not attributable to adducted protein, but rather to artifacts due to insufficient 
dialysis. The concentrations at which the adducted proteins exert their reported pro-
                                                 
53 The degree of crosslink formation is correlates to the protein concentration used (unpublished data). 
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inflammatory effects are often excessively high and correspond to doses that are also toxic to 
cells [221]. Hence this may imply a titration effect of contaminants. This is especially a risk if 
MDA-modified protein is prepared ‘fresh’ and dialysis equilibrium times are cut short. Even 
one overnight round of dialysis only reduces remaining MDA by only ~1000-fold, depending 
on the excess buffer. Given that protein is modified at >50 mM, this would leave the free MDA 
contaminants somewhere below 50 µM and eventually at ~1 µM, assuming a 2 mg/mL protein 
solution is diluted to 50 µg/mL. The final concentration of contaminants would thus be well 
above toxic ranges for MDA. 
 
5) Fluorescence. The fact that MDA-derived oligomers and adducts have fluorescent properties 
interferes with readouts that rely on fluorescence as a readout, most notably FACS. MAA 
adducts display absorbance around 350-450 nm (peak at 390 nm), which may differ for various 
MDA oligomers. Importantly, there is detectable emission in FACS channels54, in particular 
FL9 and FL10, which bleed into FL1 and FL2 channels that are commonly used for detection. 
The problem is demonstrated in Figure 7 (pg. 40). Thus for analysis of MDA adducts these 
channels are best avoided, because there is a significant risk of observing skewed results. 
 
A further notion is that aldehydes can be hydrated, especially at lower pH ranges. Alternatively, 
aldehydes can also be metabolized by aldehyde dehydrogenases to the corresponding 
carboxylic acid. Both these mechanisms affect the final nature of respective adducts and 
analytical methods. In connection to alcohol-induced liver pathology it has been reported that 
deficiency of aldehyde dehydrogenase 2 worsens inflammation [222]. 
 
Lastly, vast alterations to the charge and topology of the carrier protein may cause it to 
aggregate and precipitate. Precipitation in turn will make it difficult to accurately determine 
protein concentrations and changes aspect that relate to nanoparticles as opposed to soluble 
protein. 
 
With all the above in mind it seems impossible claim any specific or homogenous modification 
with defined MDA adducts. I therefore mostly refer to MDA-modified proteins as a protocol 
rather than a specific adduct. Furthermore, the difficulties associated with MDA modification 
are important to keep in mind during the analysis, interpretation of data and especially during 
experimental preparations. 
  
                                                 
54 Relevant channels in the Gallios Flow Cytometer are explained in Figure 7. 
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Figure 7: Fluorescence of MDA adducts or soluble MDA oligomers interferes with 
FACS readouts 
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RAW264.7 macrophages were polarized towards M1 (LPS+IFNγ) or M2 (IL-4/IL-10/TGFβ), 
or treated with the indicated proteins or pure MDA oligomers for 24 h. Cells were prepared 
and stained for analysis by FACS with antibodies to the indicated targets. 
 
Top left: the FACS histograms for FL9 reveal emission for fluorescent MDA products. 
Top right: the median fluorescent intensity (MFI) quantification shows that fluorescence is 
apparent is associated to MDA modification, but significantly more evident in MDA oligomers 
used as positive control. 
Lower panel: The arrows indicate channel bleeding into mostly FL1, but also FL2. Note that 
the bleeding effect to FL2 has more impact on targets with low signal intensity (CD80) as 
opposed to strong signal intensity (PDL1). There is no signal bleeding into FL6. Signal 
bleeding may inspire false conclusions, e.g. that CD80 would be induced by OVA-MDA, 
which is not confirmed by RT-PCR (data not shown).  
 
Relevant channels in the Gallios Flow Cytometer: 
 
Channel Exitation (nm) Emmision (nm) Dye example 
FL1 488  525/40  FITC 
FL2 488  575/30  PE 
FL6 638  660/20  Allophycocyanin 
FL9 405  450/50  DAPI, Pacific Blue™ 
FL10 405  550/40  Pacific Orange™ 
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Figure 8: MDA oligomerization 
 
 
  
A) Example for two units of MDA oligomerizing. The reaction itself can propagate to 
include many more units of MDA. Tautomerism accounts for various intermediates of 
the (MDA)2 molecule, which can further undergo dehydration to create a more 
extensive delocalized π-system, which in turn accounts for absorbance and color. 
Different oligomers can continue to react to more advanced products. 
B) Another example of MDA oligomerization involving incompletely hydrolyzed TMP. 
C) Example of a freshly prepared MDA solution and a reacted one. Note that the fresh 
solution (left) is transparent and clear, whereas the reacted solution (right) has given 
rise to red color over time. This color development is independent of the addition of 
amines. 
D) The hydration of aldehydes is acid catalyzed, reversible, and changes the nature of the 
functional group. 
E) Aldehydes can be oxidized by aldehyde dehydrogenases to carboxylic acids. 
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1.5.3 MDA IN VIVO 
1.5.3.1 MDA metabolism and molecular targets 
Soluble MDA is metabolized to CO2 inside the body with an approximate half-life of 4 h [223], 
although a major fraction is expected to react with available amines directly. Adduction may 
prolong the half-life of MDA [224]. The major carriers of MDA in vivo are apoptotic/necrotic 
cells, microvesicles and oxidized lipoprotein particles [175]. A major metabolite of MDA-
lysines, (Nα-acetly)-(Nε-propenal)-Lysine, is secreted via urine [205]. 
The reactive nature of MDA makes it likely to react with the next best amine, thus implying 
membrane proteins and enzymes as the major targets. Mass spectrometry approaches have been 
performed in order to identify the targets of MDA modification [175, 225, 226]. Enolase has 
been identified as one of the many targets, which is interesting as enolase is also a autoantigen 
in rheumatoid arthritis [166]. While using alternative tissues may identify more targets, a major 
issue with most Mass Spectrometry approaches (e.g. 2D gel electrophoresis) is an inherent 
negative selection bias for membrane proteins. In relation to MDA being associated to lipid 
peroxidation and membranes this implies that many potential targets are possibly being missed. 
 
1.5.3.2 Association of MDA adducts to disease pathology 
Lipid peroxidation products are established markers of oxidative stress in the pathology of 
various diseases. Accordingly, lipid peroxidation has been implicated their respective 
pathogeneses although direct causality may be difficult to establish. The presence of lipid 
peroxidation markers is thus reminiscent of a ‘chicken-egg’ discussion, because the fact that 
lipid peroxidation is active does not automatically infer that it is the main culprit for 
pathogenesis. Conversely, neither does it exclude that MDA is relevant to the pathogenesis. 
There is convincing evidence for MDA being important in age-related macular degeneration 
[104] and atypical uremic syndrome [227]. Both diseases have established associations to 
mutations in complement factor H, a soluble complement component that enhances 
complement-mediated opsonization but counteracts final complex formation and pro-
inflammatory effects (reviewed in [228]). Importantly, factor H binds MDA adducts [104], 
thus establishing a link to homeostatic clearance of stressed or apoptotic cells. Conversely, 
MDA adducts are also reported to be recognized by the driving complement component C3 
[105] in turn implying a balance between clearance and pro-inflammatory activation55.  
In this context the disease involvement of MDA is established via the association to factor H 
deficiencies. These have been associated to other diseases such as lupus nephritis [229] or 
                                                 
55 Notably, tests for direct binding of C3 to MDA were negative using purified components instead of sera 
(Weismann et al., 2011, supplementary data). Factor H is a known interaction partner of C3, therefore the ELISA 
for C3 binding to MDA in (Veneskoski et al., 2011) possibly is indirect via factor H. If so, this would further argue 
in favor of anti-inflammatory recognition and clearance of MDA adducts. 
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smoking-induced lung cancer [229], possibly implying a contribution of MDA in these 
diseases. 
Based on pathology [230] MDA is associated to a range of other diseases, including liver injury 
[231], lung injury [232] and epilepsy [233]. In particular, there is an emerging role of MDA 
adducts in the pathogenesis of atherosclerosis (reviewed in [175, 234, 235]), especially its 
inflammatory aspects [236]. Briefly, MDA is linked to inflammation in atherosclerosis by the 
involvement of lipoprotein particles and their MDA-mediated overwhelming uptake into lipid-
laden ‘foam cell’ macrophages. Furthermore, ER-stress [237] and ensuing apoptosis with 
necrosis of these cells creates a perpetuating inflammatory environment. Lastly, there are 
several lines of evidence suggesting adaptive immune responses in the form of antibodies 
directed towards MDA adducts. Together these features support a role for MDA adducts in 
atherosclerosis [175, 235]. 
1.5.4 PATHOLOGICAL AND PRO-INFLAMMATORY EFFECTS OF MDA 
I will start off this chapter by clarifying my personal opinion that many of the immediate pro-
inflammatory effects of MDA are probably attributable to bystander effects associated to cell 
stress and death and the release of danger-associated-molecular patterns (DAMPs), rather than 
being specifically and directly induced by MDA adducts. This is largely based on my personal 
endeavors throughout my PhD in failing to establish clear pro-inflammatory effects of MDA-
modified protein. However, the typical dose of 50 µg/mL I applied in my research projects is 
far below what most publication use in conjunction with effects related to MDA-adducts 
(typically >200 µg/mL), but the effects I observed on uptake and proliferation were already 
clear (cf. discussion of Study I). 
 
1.5.4.1 Modification of nucleic acids and mutagenesis 
MDA exerts toxic effects to cells starting 
at doses around 100 nM [205]. This 
toxicity can be attributed both to protein 
and lipid modifications, but also to DNA 
modification [238, 239]. All nucleic 
acids can be modified by simple MDA-adducted derivatives, 
but most notably guanine that can be modified by MDA and 
condensate further to a cyclic-adducted variant called 
M1G
56. [239]. M1G is an established marker of DNA damage 
and has mutagenic and carcinogenic effects and furthermore 
MDA adducts in DNA arrests transcription [240]. Thus 
                                                 
56 MDA-Guanine (pyrimido[1,2-a]purin-10(3H)-one) 
Figure 9: M1G 
Structure of M1G. The original 
guanine residue is shown in 
black. The ambiguous R 
corresponds to a hydrogen in 
MDA-guanine, or the sugar 
backbone in MDA-guanosine 
residues. The cyclic MDA 
adduct is shaded grey. 
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while MDA is toxic to cells and induces DNA damage, this attribute is largely lost if MDA is 
bound to protein. 
 
1.5.4.2 Release of pro-inflammatory cytokines 
A number of studies have reported the release of cytokines in response to exposure to MDA-
modified protein.  
The human THP-1 cell line induced CCL2, IL-6, CCL11, CXCL13 after stimulation with 
50 µM MDA or MDA-lysine [241] and produces IL-8, IL-1β, TNF-α, and IL-12β after 
stimulation with 50 µg/mL of MDA-BSA cells [104]. IL-25, IL-6 and IL-8 were induced in 
the Jurkat T cell leukemia line and human peripheral blood lymphocytes treated with MDA 
[242].  
In mice, CXCL1 (KC) gene expression was induced in retinal pigment epithelium (RPE) 
assayed ex vivo 6 h after injection of MDA-BSA into the eye. Mouse bone marrow-derived 
macrophages in the same study required >100 µg/mL of MDA-BSA to induce ~100 pg/mL of 
CXCL1 in vitro [104]. 
Rat liver endothelium or Kupffer cells were reported to secrete increased TNF after co-
incubation with MDA-BSA at 25 µg/mL and LPS, compared to LPS alone [243]. Similarly rat 
hepatic stellate cells were reported to dose-dependently secrete CCL2 and CXCL2 in response 
to MDA-BSA (up to 100 µg/mL) [244]. 
Personally, I have performed ELISAs for TNF secretion by either mouse bone marrow-derived 
macrophages (WT and CD36 knockouts) or RAW264.7 cells incubated with 50 mg/mL of 
MDA-proteins, but observed no induction other than in positive controls. I think it is unclear 
whether these cytokines are in fact released in response to MDA-modified protein, or rather as 
a consequence of cellular stress and/or death. 
 
1.5.4.3 Other pathological effects of MDA 
Besides pro-inflammatory cytokine release there are a few pathological effects associated with 
MDA or MDA-modified proteins. For instance, MDA modification has been reported to 
interfere with the function of hemoglobin [245]. Other studies report MDA-modified proteins 
to stimulate pro-inflammatory and pro-fibrotic processes [246], vascular injury [247] or 
damage to lung tissue [232]. Apart from the above notions, there have been implications for 
MDA adducted proteins challenging lysosomal integrity [248], inducing ER stress and 
interfering with processing events [249]. The latter issues have been addressed in the context 
of Study I. Lastly, it is possible that APCs chemically reduce presented aldehyde antigens 
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[250]. However, it is not established that the adducts themselves actually represent T cell 
epitopes and their size extension would argue against it.57 
 
1.5.4.4 Signaling induced by MDA 
Lastly, MDA or its adducts have been implied to induce cellular signaling, although how this 
occurs is mechanistically poorly elucidated. Activated pathways include protein kinase C γ 
(PKCγ) [251], mitogen-activated protein kinase 1/ extracellular signal–regulated kinase 
(MAPK/ERK 1/2) and nuclear factor kappa B (NFκB) [222]. I discuss below that possibly co-
recognition by scavenger receptors and TLRs induces signaling. Furthermore, oxidized 
phospholipids possibly modulate the cellular signaling [252]. The signaling mechanisms of the 
related advanced glycation end products are reviewed elsewhere [253].  
 
1.5.5 INNATE RECOGNITION OF MDA ADDUCTS 
MDA modification profoundly changes the biochemical properties of the carrier protein [202, 
254]. In particular the adduction of lysine amines eliminates positive charges and drastically 
changes the residue’s topology. These changes convey properties that can potentially be 
recognized by innate pattern recognition receptors (reviewed in [255]). Specific recognition of 
MDA adduct is thus possibly a basis for inducing innate immune responses. 
1.5.5.1 Recognition by scavenger receptors 
Recognition of adducts associated with oxidative stress is widely accepted to entail recognition 
by components of innate immunity [183, 255]. This inspires the conclusion that such adducts 
constitute a novel type of DAMPs [256]. 
Scavenger receptors are groups of heterogeneous receptors that recognize a wide range of 
ligands or patterns with implications for clearance and innate immunity (reviewed in [161]). 
Various MDA-modified proteins have been demonstrated to be selectively phagocytosed by 
Scavenger Receptor A (SRA) [221, 248, 257-260], CD36 [258, 261] and possibly LOX1 and 
FcγRIII (CD16) [261]. Importantly, SRA is undoubtedly the main receptor for MDA-adducted 
protein and I have extensively addressed this in Study I. CD36 is mostly reported as a receptor 
for MDA adducts in the context of LDL, while CD36 is the prototype scavenger receptor of 
oxidized LDL (oxLDL) [161]. MDA in turn has been suggested as one dominant component 
of oxidized LDL [262]. The binding of MDA-LDL by LOX1 and FcγRIII has also been 
                                                 
57 This is a major issue with MDA compared to small PTMs such as citrullination or acetylation. While the latter 
can be easily accommodated during antigen presentation, MDA adducts are generally much too bulky and are 
expected to sterically obstruct MHC and TCR interaction should they be present in the MHC groove. While 
citrullination alters the charge of former arginine residues, the volume is essentially the same. Conversely, MDA 
adduct render the modified lysine residue roughly twice as large. 
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demonstrated, although the relative binding is >15-20 times lower than for SRA (cf. [261]). 
The FcγIII receptor is important for monocytes [263] and has been implied to be critical for the 
induction of EAE, although the relative importance differs between independent publications 
[264, 265]. 
The ligation of scavenger receptors has been implied to possibly contribute to the maturation 
of DCs [266]. The complication is that the known scavenger receptors feature very short 
cytoplasmic tails devoid of classical signaling motifs. Conversely, it is starting to emerge that 
scavenger receptors utilize or modulate the signaling of other pattern recognition receptors, e.g. 
TLR4 upon co-ligation [261]. This is very interesting as it opens up new possibilities and 
implies that the nature of the (modified) ligands influences the cellular responses. 
1.5.5.2 Recognition by complement 
As discussed above, MDA adducts have been reported to be recognized by complement factors 
H [104, 227] and C3 [105], although the latter was demonstrated using serum and potentially 
mediated via factor H. Nonetheless, these studies highlight the innate recognition of MDA 
adducts and establishes a link to clearance mechanisms, with potential tilting toward 
inflammation in case the clearance mechanisms are defective or depleted. 
1.5.5.3 Recognition by natural antibodies 
In addition to the innate recognition mechanisms above, natural antibodies have been 
demonstrated to recognize MDA-derived epitopes [267-269].  
1.5.5.4 Conclusions on innate recognition. 
Together these observations imply evolutionary advantages with innate recognition of lipid 
peroxidation products. This suggests that the mechanisms described above mostly exist to limit 
potential damage associated with lipid peroxidation and reactive products thereof. 
Furthermore, this conchords with the association of MDA adducts to cellular stress, death and 
debris. The common denominator of innate recognition appears to be clearance, rather than 
inflammation. Notably, this does not exclude that inflammation could occur in response to non-
apoptotic cell death and release of DAMPs if the situation cannot be contained. Lipid 
peroxidation in vivo is very common and inevitable, much as the occurrence of many other 
PTMs. I therefore think that default pro-inflammatory responses to such events would be 
detrimental.  
 
1.5.6 MDA AND ADAPTIVE IMMUNITY 
In continuation to innate recognition I will discuss adaptive responses to MDA adducts. As 
discussed earlier there are mechanistic connections that imply a role for MDA in the pathology 
of many inflammatory diseases involving adaptive immunity.  
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It appears that MDA modification has gained the status of a hapten [270] that converts the 
carrier antigen to a ‘superantigen’ of sorts. This is based on a series of studies reporting that 
MDA-adduction breaks immunological tolerance [271, 272]. Typically, elevated T cell 
responses [221, 273] and levels of autoantibodies [274, 275]58 are reported as a consequence 
of MDA-adduction to the carrier protein. The climax is the claim that MDA-modified proteins 
are immunogenic per se in the absence of adjuvant [276]. 
However, there is a flip side to the coin, namely that adaptive immune resonses towards MDA 
potentially constitute ‘protective autoimmunity’ [277] in a sense that it augments clearance 
mechanisms discussed further above. There are several studies implying that MDA-directed 
adaptive immunity is protective in atherosclerosis [278-282], although this is challenged by 
anti MDA-LDL antibodies being suggested as a potential negative predictive marker in 
cardiovascular disease [283]. Together these studies call for approaches to establish 
standardized methods for the reliable detection of antibodies recognizing MDA adducts [284], 
and the contextual investigation of adaptive immunity [175] in order to clarify the role of 
MDA adducts and antibodies towards them. 
We currently understand that adaptive immune responses to MDA adducts are dependent on 
CD4+ cells [285], MHC class II and functional TCRs [286]. Advanced glycation endproducts 
(AGEs) and advanced lipoxidation endproducts (ALEs) notably share many common features 
[183] and antibody cross-reactivities have been identified [287]. Furthermore, there is cross-
reactivity between MDA antigens and bacterial antigens [288]. 
Future studies will be required to elucidate the specificities and involvement of adaptive 
immunity towards lipid peroxidation products. 
 
1.5.7 REFLECTIONS ON MDA 
In conclusion, I have tried to review the current knowledge regarding MDA and its adducts 
from my personal (flavored) perspective. In light of the abundance in literature about the many 
properties of MDA or its adducts, major criticism towards some of the conclusions may appear 
unwarranted. I am nonetheless concerned that certain pro-inflammatory effects attributed to 
MDA adducts are not necessarily well established, as there is implicit evidence that these may 
be artifcats related to soluble MDA. However, neither do I present conclusive evidence to the 
contrary, nor can these processes be dissociated in vivo, but there are arguments to be made 
about the doses. Adaptive inflammatory immune responses towards carrier proteins of lipid 
peroxidation would bear a serious risk for the development of autoimmunity, in analogy to 
firefighters using oil instead of water. This assumption has been the reasoning behind the 
conception of my original study plan. Conversely, articles related to uptake by scavenger 
                                                 
58 Duryee et al. (2008) suggested that MDA-modification could even be exploited in tumor immunotherapy. 
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receptors and clearance mechanisms agree with my own results and make significantly more 
sense from a homeostatic biological perspective. My personal experiences compel me to taking 
this standpoint but likewise make me dismiss previous conclusions. Though this is based on 
own results one may rightfully question my objectivity on this matter. Hopefully future studies 
may eventually address some of the concerns and shed light on the discussion about what the 
effects of MDA adducts truly are. 
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2 ETHICAL CONSIDERATIONS 
Ethical considerations and statement are becoming more common in scientific publications. 
However, in many cases the focus is essentially limited to animal experimentation and the 
discussion continues until people arrive at the conclusion that animal experimentation is 
irreplaceable and should be performed according to humane guidelines while using adequate 
alternatives wherever possible. The latter is my summary on that matter. I have done everything 
by the book and have a clear conscience because I considered every possible replacement, 
reduction and refinement to abide by ethical principles. Animal experimentation only applies 
to a minority of scientists and is a special scenario. I would rather discuss more universal ethical 
considerations related to research and publishing ethics.  
Every scientist has a personal responsibility to design, perform, document, analyze, interpret 
and communicate their research in a fashion that will ultimately support valid conclusions. 
Sustainable science is thus indirectly a product of practiced ethical philosophy. In reality it may 
be harder to avoid the pitfalls of bias and wishful thinking, but that also requires the awareness 
to recognize them. Conviction carries the hidden danger of accepting results that support the 
prevailing hypothesis and dismissing results to the contrary, therefore blinding and critical 
evaluations ought to be applied more often. Self-criticism defines the scientist.  
In modern research the demands to securing funding and publishing have increased 
significantly, leaving little room for failure. I perceive the ‘publish-or-perish’ pressure to 
promote a culture in which newsworthiness is valued over quality, and positive results valued 
over negative ones. However, negative results do not necessarily equal inconclusive results and 
personally I have learnt a great deal from experiences and experiments that did not work out as 
expected. I approached my study plan with the conviction that I would gather evidence to prove 
the concept, but gradually changed my attitude as I grew more confident in my own conclusions 
that were in disagreement. Science in general always appealed to me because it is based on 
reasoning and logical principles in the pursuit of knowledge and truth. This ideal was shattered 
by the reality that ultimately there are only results and conclusions, some more solid than 
others. In this continuous discourse of evolving hypotheses applied scientific ethics really 
matter. Dynamic hypotheses can only be shaped based on valid data and if there is no 
conflicting political interest favoring a dogmatic interpretation. Only prevailing against long-
term independent and objective scrutiny lends a hypothesis increasing credibility. A pivotal 
basis is thus performing honest science with dedication to detail in every aspect and to the best 
of capabilities and circumstances. There are many approaches to research, but striving for 
perfection is the only way to do science. 
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3 DISCUSSION OF STUDIES 
This section is dedicated to the more general discussion of the studies. In order to avoid 
redundancy to the existing introductions and discussions of the individual studies, I intend to 
give a wider background and perspective in addition to the independent studies. I chose not to 
review methods in the thesis because it felt redundant to the individual studies and would not 
have reached a sufficient level of detail to allow for an enlightening discussion. Instead I 
attempted to mention the motivation and caveats of certain approaches along the way. Below 
is a condensed overview of the respective studies. 
S
tu
d
y
 I
 
“Scavenger Receptor A mediates the clearance and immunological screening of 
MDA-modified antigen by M2 type macrophages” 
 
Aim 
Assessment of the immunogenicity and uptake of MDA-modified MOG 
 
Methods 
Biochemical methods, FACS, ELISA, in vitro cultures and EAE 
 
Results 
Using fluorescently-labeled MOG and MOG-MDA it is demonstrated that enhanced 
uptake of MOG-MDA is mediated by SRA and associated with M2 macrophages. In 
vitro proliferation of 2D2 cells is maximized by enhanced uptake of MOG-MDA but 
EAE induction is equivalent. 
 
Conclusion 
MDA-modified antigen is mainly cleared by M2 macrophages via SRA but is also 
presented to T cells 
 
S
tu
d
y
 I
I 
“PyTMs: a useful PyMOL plugin for modeling common post-translational 
modifications” 
 
Aim 
The creation of a simple tool for molecular modeling of PTMs 
 
Methods 
Implementation of a plugin for PyMOL and concept testing 
 
Results/ Conclusion 
The PyTMs plugin can be successfully used to address research questions relating to 
PTMs with certain caveats. 
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S
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II
 
“Nitration of MOG diminishes its encephalitogenicity depending on MHC 
haplotype” 
 
Aim 
Characterization of the immunogenicity of nitrated MOG 
 
Methods 
Biochemical methods, molecular modeling, FACS, in vitro cultures and EAE 
 
Results 
Y40 is a critical anchor residue occupying the p1 pocket during presentation by H2-
IAb. The APL nitrated at Y40 is predicted not to be presentable due to its structural 
incompatibility with the p1 pocket. Nitrated MOG abrogates in vitro proliferation of 
2D2 splenocytes and is not encephalitogenic in the EAE model for C57BL/6 mice, but 
is fully encephalitogenic in DBA1 mice. 
 
Conclusion 
Nitration of the critical anchor residue Y40 denies presentation of the MOG35-55 epitope 
by H2-IAb in C57BL/6 mice, but the MOG79-98 epitope in DBA1 mice is unaltered and 
retains fully encephalitogenic. Nitration is a thus an MHC-dependent mechanism 
through which antigen-specific T cell responses can be negatively affected. 
 
S
tu
d
y
 I
V
 
“Rat bone marrow-derived dendritic cells generated with GM-CSF/IL-4 or 
FLT3L exhibit distinct phenotypical and functional characteristics” 
 
Aim/Methods: 
The functional and phenotypic aspects of rat bone marrow-derived dendritic cells 
(BMDCs) generated with either GM-CSF/IL-4 (G4) or FLT3L (FL) were compared 
using FACS, RT-PCR, Cytokine Bio-Plex and T cell proliferation assays. 
 
Results/ Conclusion 
G4-BMDCs excel at phagocytosis and express CD11b and CD11c, whereas FL-
BMDCs express CD103 and CD4. FL-BMDCs have a stronger upregulation of class 
II and co-stimulatory molecules upon activation and induce antigen specific T cell 
proliferation and skewing towards Th1 and Th17 subsets, unlike G4 that promote 
IL-10-producing Tregs and induce poor T cell proliferation. The BMDC cytokine 
profiles differ. 
The respective BMDCs are functionally and phenotypically distinct.  
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3.1 STUDY I: “SCAVENGER RECEPTOR A MEDIATES THE 
CLEARANCE AND IMMUNOLOGICAL SCREENING OF MDA-
MODIFIED ANTIGEN BY M2 TYPE MACROPHAGES” 
3.1.1 HISTORIC CONTEXT OF STUDY I 
The design of this project was originally an entirely different one. According to my study plan 
I was supposed to investigate the use of MDA-modified MOG as a tolerance-inducing vaccine 
[289]. There are two underlying studies performed by a former PhD student in the lab several 
years before me that I will need to introduce to give a background [272, 289]. I will do so by 
summarizing the essential data according to the original figures, but I do recommend reading 
them separately. The focus in on the study related to MDA [272]. 
 
“Vaccination with myelin oligodendrocyte glycoprotein adsorbed to alum effectively 
protects DBA/1 mice from experimental autoimmune encephalomyelitis” [289]. 
Figure 1 An ALUM-based vaccine preparation of MOG protected DBA1 mice 
from EAE if injected in advance 
Table 1 The above only worked i.p.; MOG-IFA conveyed the same effect. 
Figure 2 The injection MOG-CFA s.c. evokes T cell responses in inguinal lymph 
nodes, but MOG-ALUM i.p. does not; both induced equal responses in 
mesenteric lymph nodes. Prior vaccination with MOG-ALUM followed 
by a challenge with MOG-CFA increased mesenteric responses, but 
reduced inguinal responses. Splenic responses were equal.  
Figure 3 MOG-ALUM vaccination prevented the migration of CD4+ or 
CD4+CD25+ T cells into the CNS 
Figure 4 MOG-ALUM vaccination is characterized by a reduction of MOG-
reactive IgG2a and an increase in IgG1 
Figure 5 CD4 knockout DBA1 mice are not protected by MOG-ALUM 
vaccination59  
Figure 6 An analysis by RT-PCR of ex vivo re-stimulated T cells detected reduced 
IFNγ and IL-10 from vaccinated mice 
The mechanism by which this supposedly induces tolerance is unclear. In modern approaches 
I would probably look at the induction of Treg cells or anergy. What puzzles me is that the 
vaccine only works i.p. but not s.c. and targets different lymph nodes than the s.c. CFA-based 
EAE induction. I did perform a larger experiment using s.c. vaccination60, but that did not 
confer protection in C57BL/6 mice.  
                                                 
59 I’m surprised these mice develop EAE 
60 Our current ethical permits did not allow for i.p. immunizations 
  55 
“Malondialdehyde modification of myelin oligodendrocyte glycoprotein leads to 
increased immunogenicity and encephalitogenicity” [272] 
Figure Reported data My concerns 
1 MOG-MDA has a lowered 
isoelectric point. Mass 
Spec detects simple MDA 
adducts at K30, K80 and 
K114, but not K55 or K73. A 
corresponding 3D model is 
presented. 
 The presented model used simple N-propenal 
lysine MDA adducts, although Mass Spec will 
additionally identify advanced MDA adducts if 
they are included in the search. 
 K55 is the most accessible lysine residue in 
MOG and is normally modified (possibly cross-
linked), K73 is inaccessible though.  
 The display with electrostatic surface potential 
is misleading because the electrostatic map does 
not apply to the modified residues, making them 
appear white. 
 A further errata is that the article reports a more 
positive charge by MDA modification, although 
this should correctly be negative instead, 
especially if the pH is above the pI (which it is). 
 Rat MOG precipitates and aggregates heavily 
by MDA modification. 
2 MOG-MDA, but not 
MOG, evokes fatal EAE in 
DBA1 mice 
 I failed to reproduce this observation using 
mouse MOG both in C57BL/6 and DBA1 mice 
in blinded experiments. 
3+5 Enhanced T cell 
proliferation towards 
MOG-MDA, inhibitable 
by poly I:C 
 I could fully reproduce this phenotype using 
2D2 cells in vitro, but not with ex vivo lymph 
nodes from immunized mice (probably due to 
the low frequency of specific T cells). Study I 
confirms that the enhanced proliferation is due 
to uptake by SRA. Minor: although used as a 
competitor here, poly I:C is a TLR3 ligand. 
4 Higher uptake of MOG-
MDA by macrophages, 
detected by intracellular 
His-tag staining and flow 
cytometry 
 The supplementary data of Study I demonstrates 
that the intracellular His-tag staining produces 
artifacts. This method fails to reliably detect 
MOG inside cells and severely underestimates 
the degree of uptake. The minor differences 
observed in the reported figure possibly relates 
to channel bleeding (cf. Figure 7, pg. 40). 
6 Induced gene expression of 
IL12R, IL-12 p35 and IL-
23 p19 in macrophages in 
response to MOG-MDA 
 I have tried to detect increased cytokines by 
ELISAs and RT-PCR approaches without 
success. 
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3.1.2 DISCUSSION OF STUDY I 
3.1.2.1 Challenges concerning mouse MOG production 
My initial challenge was to produce mouse MOG and the MDA modification for EAE 
induction. The older preceding studies used rat MOG and DBA1 mice, but we were to transition 
to mouse MOG and C57BL/6 because this strain is more commonly used and offers a 
significantly wider variety of transgenic models and tools. Secondly, there is no justified 
motivation to use rat MOG in mice as this may entail artificial mechanisms due to sequence 
differences (discussed in Study I). In essence, the goal was to establish a working model. 
My initial problem was that the production of recombinant MOG did not yield pure enough 
protein and contained aggregates. Since one aim was to compare the immunogenicity I wanted 
to avoid any artifacts related to bacterial contaminants or protein aggregation. A second 
motivation was to optimize both yield and purity because at the time one of the study goals was 
to possibly resolve a crystal structure of MDA-modified MOG. Over time I invested extensive 
efforts to polish the MOG production, which was eventually upgraded from a very labor 
intensive and time-consuming manual process to a standardized automated production. By 
joining His-tag affinity chromatography with an ion exchange chromatography this method is 
able to specifically isolate monomeric folded protein and get rid of misfolded and aggregated 
protein. The process as a whole has been at the heart of my PhD studies and is depicted in 
Figure 10, but is too extensive to describe here in full detail. 
  
The automated production of monomeric mouse MOG is a multistep process involving two main 
methods: Immobilized Metal Affinity Chromatography (IMAC) and Ion exchange 
chromatography (IEX). 
A) The recombinant His-tag binds immobilized Ni2+ ions on the IMAC column. Various 
impurities are removed in a series of steps involving different elution conditions. Subsequently 
residual endotoxins such as LPS are removed by two approaches (precipitation and extended 
elution with Triton X-114). The column is equilibrated, the protein denatured again and 
allowed to refold in place. After final washing steps, the fraction F3 is eluted (purified MOG). 
B) The F3 fraction is directly loaded onto and IEX column for further removal of contaminants 
and polishing. The F4 fraction does not bind the column, F5-F7 are eluted after washing with 
increasing amounts of salt. 
C) Analysis by SDS-PAGE and Coomassie staining with either reducing or non-reducing 
conditions. Under reducing conditions MOG yields 1-2 bands implying a high efficiency of 
purification from the extract. However, reducing conditions reveal that F3 still contains 
misfolded multimers of MOG that are sensitive to reduction. These multimers are separated 
by IEX into F4 (aggregated column non-binding), F5 (monomeric MOG, one band!), F6 
(mostly dimers) and F7 (mostly trimers). F5 is the final product used for experiments after 
dialysis to PBS. 
 
CV=column volumes. Note the insert legend for the graphs. Asterisks indicate the reason for 
unexpected absorbance. Fractions (F) are indicated. 
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Figure 10: Production of purified monomeric mouse MOG 
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3.1.2.2 Challenges concerning MOG-MDA and the EAE phenotype 
Several analyses reproduced the biochemical features of MOG-MDA, but also led to a more 
diversified approach in respect to the advanced MAA adducts. I quickly recognized that the 
homogenous modification with MDA is a myth due to the lack of control over the chemical 
reactions, but also that the instability and heterogeneity would not be suitable for clinical 
applications, i.e. vaccines. If anything, one would require defined and stable modifications that 
mimic the effects of MDA. 
A very consistent result was that MOG-MDA did enhance the proliferation of 2D2 splenocytes. 
The fact that we observed increased proliferation in vitro always motivated the expectation that 
the EAE phenotype should be more severe. However, I failed to produce evidence that MOG-
MDA in fact evokes more severe EAE. The challenge in this respect is that the EAE model is 
already very harsh and artificial. I theorized that if MOG-MDA was indeed more 
immunogenic, there should be conditions at which it evokes EAE, but not native MOG itself, 
but it is almost impossible to identify such a condition in the EAE model.61 
I have tried immunizing both C57BL/6 and DBA1 mice with variable doses of MOG and 
different adjuvants (IFA, CFA with variable doses) without noting differences as clear as they 
were previously reported [272] (cf. Study I and Figure 11C). After the initial experiments I 
went over to blinding myself for all in vivo experiments to minimize my personal bias. Issues 
related to the use of MDA-modified rat MOG are discussed in Study I. Briefly, the MOG79-98 
epitope in DBA1 mice [115] contains an amino acid substitution62. It was demonstrated for the 
human MOG35-55 epitope
63 in C57BL/6 mice that the EAE is instead driven by B cell-dependent 
mechanisms and requires a secondary response to endogenous MOG [32, 122]. This may imply 
that MDA adducts possibly enhance this process, possibly by overriding the necessity for 
MOG-specific B cells with additional MDA adduct-specific B cells, although this is pure 
speculation.  
Apart from the regular amino acid substitutions between species the rat MOG construct features 
additional amino acid extensions on both the N- and C-terminus and uses a different linker to 
the His-tag [290], which confers alternative biochemical properties compared to the mouse 
construct. In relation to this a second aspect is that MDA modification causes precipitation of 
both rat and human MOG (cf. Figure 11B, pg. 61). The original article states: “Protein was 
separated from unreacted free aldehyde by two rounds of dialysis against PBS. The precipitate 
was removed through centrifugation […]” [272]. For me this sentence implies two things: 
firstly, that the two rounds of dialysis were insufficient to reliably remove soluble MDA, and 
secondly, that the protein was heavily aggregated. Micro-aggregates relating to the latter cannot 
                                                 
61 Imagine you wanted to show that there was a difference in temperature between tea and iced-tea, but would 
have to throw the cups into a burning volcano to measure the temperature. Replace the teacups with MOG/ 
MOG-MDA and the volcano with CFA and you will be essentially looking at the problem with the EAE model. 
62 GKVTLRIQNVRFSDEGGY, rat: 82=A, mouse 82=T. 
63 MEVGWYRSPFSRVVHLYRNGK; human 42=P. 
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be reliably removed by centrifugation, either. These may cause altered immune recognition and 
make it difficult to reliably determine the protein concentration, probably underestimating it. 
The fact that a considerable fraction of protein is lost to the precipitate lowers the concentration 
and, accordingly, the dilution factor for contaminants64 (discussed further below). Lastly, it is 
unclear how representative the soluble fraction of rat MOG-MDA is of the entire preparation. 
3.1.2.3 A reflection on protein doses used in EAE 
A mouse brain weighs approximately 0.5 g wet weight, the brain protein content is <10%, 
MOG is ~0.05% of myelin protein. That yields: 0.5𝑔 × 10% × 0.05% = 25µ𝑔 
In other words, if I immunize a mouse with 50 µg of MOG, there is roughly twice as much 
MOG in its tail base than in its entire brain. Exposing 2D2 cells to 50 µg/mL of MOG 
corresponds to isolating all MOG from one mouse brain and diluting it in just 1 mL. The point 
is that these experiments are already highly artificial. Dialing up the dose in hope of effects 
would simply add to the existing artificialness.  
3.1.2.4 Chicken-egg. Soluble MDA or MDA adducts – can the effects be dissociated? 
I intended to perform a proliferation assay with 2D2 cells using freshly modified MOG-MDA, 
so I modified MOG with MDA for 3 h and subjected it to several rounds of dialysis against 
PBS for ~2 h each while preparing the 2D2 splenocytes in parallel. According to the 
manufacturer of the dialysis cassettes complete buffer exchange is achieved within 2 h, but this 
is based on the dialysis of salt using membranes with significantly larger pores. All 2D2 cells 
exposed to MOG-MDA died in the experiment. For a subsequent repeat I had re-dialyzed the 
same batch along with a more properly dialyzed independent batch. Titration experiments 
revealed the typical increased proliferation towards MOG-MDA over MOG, but also a 
remaining toxicity at higher doses (Figure 11C). My conclusion from this experience was that 
MDA toxicity exists in preparations of MDA-modified protein, and has to be removed 
extensively if the aim is to address the effects of the adduct without over-layering effects of 
soluble contaminants. I subsequently invested some efforts using tracers to optimize the 
dialysis step, which revealed that establishing equilibrium takes several hours (~6 h), and that 
dialysis needs to be performed over several equilibria (>4x) to reliably remove contaminants.  
The above rendered me skeptical towards reports attributing certain effects to MDA adducts as 
opposed to the possibility that soluble contaminants may also account for them. It struck me 
that the majority of reports on the pro-inflammatory aspects of MDA were authored by the 
same core group of authors, implying a lack of independent reproduction. Startlingly, some of 
these studies report the toxicity of MDA-modified proteins in vitro at above 100 µg/mL 
[221]65, but they immunized animals with a dose corresponding to 125 µg/mL. Subsequently 
they observe elevated immune responses towards MDA-modified antigen, but conclude that 
                                                 
64 A lower protein concentration will require more input to achieve the same concentration.  
65 Simply truncating data in the corresponding graphs. 
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this is attributable to the MDA adducts alone [221, 276], while cell death is either ignored or 
attributed as a specific effect of adducts [248]. Conversely, I failed to detect lysosomal 
instability [248] (cf. Figure 11E) or synergy with LPS for TNF secretion [243] with MDA-
modified protein. Personally, I went from accepting the above-mentioned conclusions as fact 
to seriously questioning their validity. Applying Ockham's razor, the simple explanation is that 
MDA-induced cell stress and death result in the release of DAMPs, accounting for the immune 
stimulation. 
Accordingly, a new open question arises: is it even possible to dissociate the effects of lipid 
peroxidation and antigen modification in vivo? After all these processes can be separated in 
biochemical research, but will occur indiscriminately in vivo. There is no definitive answer to 
this question, but in vivo there are more factors involved, yet the concentrations of MDA are 
also expected to be significantly lower. 
3.1.2.5 Uptake and M2 macrophages – a role for the innate recognition of MDA adducts 
One centerpiece of Study I is the uptake by SRA. Although the approach is very elegant and 
conclusive I should point out that this is not a novel discovery. Critics may rightfully argue that 
this is just a fancy way of demonstrating what we already know. However, the novel aspects 
are the association to M2-type macrophages [291] and effects on digestion.  
The notion that innate recognition of lipid peroxidation products by SRA primarily associates 
to macrophages with homeostatic phenotypes agrees with the concept of clearance and tissue 
repair. It also explains why no differences are to be expected in the priming of EAE, since 
classical DCs do not express SRA. However, it somewhat disagrees with the in vitro 
proliferation results of 2D2 mice. One simple explanation could be the abundance if protein 
suffices for presentation by all APCs and induces in vitro proliferation regardless. The fact that 
blocking SRA actually reduces proliferation would argue against this. A potential consensus 
would be that although the antigen is effectively taken up, it is also is presented for potential 
recognition by memory T cells, in case the tissue damage is in fact associated to a pathogen. 
Furthermore, different populations of APCs possibly respond in a variety of ways to identical 
stimuli [292-294]. 
The observation that MDA adducts interfere with digestion of carrier antigens seems 
expectable, but has important implications. Although I did not identify any reason to believe 
the digestion of MOG by macrophages would be affected, this may differ for other antigens. It 
could furthermore prolong the half-life of protein debris in the extracellular space. I wonder 
whether a potential inability to process certain cargo may contribute to the phenotype of ‘foam 
cell’ macrophages in atherosclerosis, besides the overwhelming uptake of lipids associated 
with oxLDL. The inability to handle the immense amount of cargo is one factor that possibly 
leads to metabolic stress and non-inert forms of cell death of these cells, which contributes to 
the inflammation in atherosclerotic lesions. 
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Figure 11: Additional data related to Study I 
 
  
A) Immunohistochemical staining of MDA adducts (brown) in a section of a CNS infiltrate in EAE 
spinal cord. The tissue is stained with hematoxylin. This staining implies that MDA is associated with 
CNS inflammation. 
B) Precipitation of human and rat MOG by MDA modification. recombinant human, rat an mouse MOG 
(tubes left to right) were modified using MDA. Unlike mouse MOG, human and rat MOG developed 
immediate turbidity (upper picture). Centrifugation of aliquots precipitated macro-aggregates in 
human and rat, but not mouse MOG (lower picture). 
C) Thymidine incorporation assay of 2D2 splenocytes using two batches of MOG and MOG-MDA that 
were insufficiently dialyzed. Proliferation is enhanced by MOG-MDA at doses from 25-200 µg/mL 
(due to increased uptake as I demonstrate in Study I). However, at excessive doses the hidden toxicity 
of soluble MDA becomes apparent. High doses of extensively dialyzed OVA-MDA did not induce 
cell death (data not shown). 
D) EAE in DBA1 mice using MOG or MOG-MDA(25µg in CFA). Note that the batches differ from C 
and were dialyzed. 
E) RAW264.7 cells were exposed to the indicated proteins or soluble MDA for 24 h and stained using 
acridine orange (AO). The fluorescence of AO is pH dependent, and it stains acidic lysosomes red 
and develops green fluorescence when bound to RNA/DNA. The analysis revealed that lysosomes 
were intact in controls and protein-treated cells, but displayed evidence of disintegration (cytoplasm 
acidification, yellow stains) along with evident cell death and debris. My interpretation is that soluble 
MDA accounts for lysosomal instability and cell death, but not its adducts. 
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In summary, a unified scenario would be that MDA-adducted protein constitutes a clearance 
signal for SRA on M2 macrophages that initiate tissue remodeling and repair in response to 
lipid peroxidation. Simultaneously, the debris is processed and presented in order to allow 
surveillance against possible pathogens, or otherwise recognition of self-epitopes by Tregs. 
However, should these macrophages become activated by additional stimuli in the surrounding, 
i.e. DAMPs or PAMPs, this would also upregulate their ability to respond to infection and 
propagate inflammation if required. This study also raises questions about the reactions of 
different monocyte/macrophage populations to lipid peroxidation products in vivo [292, 295]. 
 
3.1.3 WHAT COULD HAVE BEEN DONE DIFFERENTLY? 
In retrospect I would do many things differently concerning this work. Mainly I would not run 
into many of the obstacles I had to learn to circumvent and deal with, yet that was a great part 
of the learning experience. I question whether I would embark on this project again at all, or 
rather do something entirely different. 
If it had to be this project I would come in with much more criticism to the inherited study plan. 
Some of the experimental procedures would be performed differently, but I regard those as 
evolutionary with small improvements or conscious changes contributing to increasingly solid 
experimentation. 
It would be interesting to replicate certain experiments that I have criticized above. I have most 
issues with the claim that MDA adducts are immunogenic per se [221, 276]. By performing 
similar experiments but controlling for the amount of soluble MDA in the preparations, I could 
possibly shed light onto the mechanism and formally establish a functional dissociation of 
soluble MDA and its adducts. I could have also immunized DBA1 mice with suboptimally 
dialyzed MDA-modified rat MOG for EAE, but I did have one occasion where I added soluble 
MDA to an emulsion of MOG that developed severe EAE (data not included). Although some 
of these experiments are feasible to perform, I am uncomfortable with potentially initiating an 
upsetting political climate. Pointing fingers implies that three fingers are pointing back at me 
and although we aspire to produce flawless science, we are human and make honest mistakes. 
Therefore, I believe that discussing these aspects rather than being aggressive about it is the 
better option, and researchers should establish their own opinion on the matter. 
With regards to Study I some it would be interesting to elucidate the transcriptome and 
signaling networks of various SRA-expressing cells in response to stimulation by either 
protein, MDA-modified protein, or MDA alone (cf. [292]). This would give unbiased insight 
into the gene expression profiles and processes in response to these stimuli. Respecting the 
notion that SRA ligation possibly modulates various responses of TLRs via co-recognition of 
the same antigen and complex formation, it would be interesting to address this using linked 
ligands with both MDA adducts and e.g. LPS. 
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Lastly, if it had to be the EAE model it would be interesting to evaluate a new mouse model. 
Since double transgenic mice with both MOG-specific TCRs and BCRs develop spontaneous 
EAE [32]. The ultimate link to lipid peroxidation having a role in pathogenesis would be if 
transgenic mice with MOG-specific TCRs and an MDA adduct-specific BCRs would display 
a similar phenotype. This is a risky venture involving the generation of a transgenic BCR mouse 
followed by additional breeding without the guarantee of success. However, if these mice, but 
not respective controls, displayed an EAE phenotype it could potentially establish a clear link 
between lipid peroxidation and CNS autoimmunity. 
 
3.1.4 CONCLUSIONS FOR STUDY I 
The scientific conclusions are stated above and in the study itself. This section has focused on 
covering the circumstances surrounding Study I and various challenges connected with it. For 
me this study is more about my personal development as a scientist. It marks the transition 
from a naïve master student struggling to obtain results that conform to the dogma of the field 
to having the confidence to shape it, based on qualitatively solid experimentation. In that 
respect I stood my ground and prevailed as a scientist. 
Concerning the immunological effects of lipid peroxidation and MDA adducts there is still 
much to be discovered. Lipid peroxidation is a pathological process and requires containment 
by the immune system to avoid propagating tissue damage and bystander inflammation owing 
to uncontrolled cell death. In this context the extent of lipid peroxidation in vivo and limiting 
antioxidant factors along with innate immune mechanisms form a complex interplay. However, 
I question that MDA adducts are in fact the ‘magic sprinkle’ that convert self antigens into 
tolerance-breaking ‘superantigens’ of sorts by default. If so this would pose a tremendous risk 
of autoimmunity, lipid peroxidation being such a common phenomenon. MDA adducts and 
other PTMs have hence been generally demonized and deserve a more diversified point of 
view. The individual interplay of PTMs in autoimmunity is significantly more complicated 
than that, and we have just seen the tip of the iceberg. 
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3.2 STUDY II: “PYTMS: A USEFUL PYMOL PLUGIN FOR 
MODELING COMMON POST-TRANSLATIONAL MODIFICATIONS” 
3.2.1 CONTEXT OF STUDY II 
This study also has its roots in the original study plan with a stated objective to resolve the 
crystal structure of MDA-modified MOG. This never happened for several reasons: Obtaining 
the large quantities of purified MOG and growing crystals for X-ray crystallography is 
technically feasible, but this is not possible for MOG-MDA. The major obstacles are that the 
modification with MDA is not homogenous, that the adducts are flexible and that they 
introduce crosslinks. A significant problem is furthermore the significant drop in yield of 
MDA-modified protein connected with approaches to re-purify specific fractions. Lastly, there 
is no specific scientific question connected to resolving the crystal structure, other than the 
topology. Given that there is a disproportionate amount of investment required to even attempt 
crystallization with significant chances of failing, it was not worth pursuing. 
At the same time I was introduced to PyMOL molecular graphics software and started figuring 
out the vast possibilities it offers. Using the basic function I started to manually build and model 
MDA adducts onto the crystal structure of MOG. This quickly made it apparent that the MDA 
adducts offered significantly more variety than previously acknowledged, especially when also 
considering advanced MDA adducts. The second realization was that it was ineffective to do 
this manually every time, and that it would be easier to reproduce on a different protein if the 
process were to be automated. That led to me developing a small script for simple MDA 
adducts. The script was expanded to include customization of the adducts, it grew more 
complex and intelligent and before long I had a custom function that could introduce MDA 
adducts on any protein. 
Why stop there? By applying the same principles I could make separate functions for other 
modifications. Later I bundled those into one plugin called PyTMs66. As I encountered 
challenges along the way this project further evolved to use a common infrastructure, deal with 
chirality, optimize positioning of larger residues, select only surface-accessible residues, 
perform co-modifications along with various other smaller improvements.  
Since I was applying this a lot in order to play around with ‘what-if’ scenarios, the ultimate 
application would be connected to my projects in predicting the extent and possible impact of 
a given PTM. Since the plugin was applicable to give more insights into structurally-related 
questions, I figured that other researchers in my situation would benefit from it. The PyMOL 
community is generally very open about sharing scripts and information publically. From there 
it was then made more user-friendly, and introduced a user interface and other additions to 
create an independent plugin.  
                                                 
66 In analogy to PyMOL and PTMs 
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3.2.2 DISCUSSION OF STUDY II 
Study II speaks for itself, so there is not much more to add. However, the really interesting 
aspects are hidden in the source code67, namely how to approach and deal with certain 
challenges related to constructing PTMs and especially sterical optimization aspects.  
For instance this involved problems with calculation times that would increase exponentially 
in order to optimize the positioning of a residue. With some optimizations of the initial concept 
several weeks of predicted calculation could be reduces to hours or minutes. I was considering 
to take up some of the details of different approaches, but I can sum it up by listing that the 
plugin will among other things scan larger intervals and interpolate only the optima68, calculate 
the strain locally rather than for the entire objects69, test initial preferences based on the residue 
without modification70, and add or include adjacent objects to account for or not (e.g. waters 
or another protein). 
I do not want to go into too much detail on the above because, despite being a useful 
functionality, it does not work the way I would want it to. Currently the optimization is residue-
based and can move the modified residue around into the optimal position. What I ideally 
would want it to be capable of performing is a holistic optimization of the entire protein instead. 
The elephant in the room is that PyMOL cannot really handle charge or protein optimization 
adequately. Current molecular dynamics simulations are performed using other software tools 
that are being developed independently for various purposes. The brick wall that one is running 
into when coming from the preclinical research side is the translational gap to structural 
bioinformatics and the steep learning curve associated with it. Especially the necessity to adapt 
to an entirely new field and the often extremely user-unfriendly tools pose considerable 
challenges. One of the intentions with the PyTM plugin was therefore to make it user friendly. 
Below I will outline some of the future challenges connected with Study II. 
3.2.3 REMAINING CHALLENGES 
3.2.3.1 Port to Python 3 
PyMOL is built on Python 2.8 but still being developed. Though no definitive date has been 
announced future PyMOL versions will be upgraded to Python 3. Currently it is already 
possible to import selected function from the future Python version, but the intent with this is 
to give people time to adapt programs and scripts instead of facing an abrupt transition. The 
important caveat is that Python has changed part of its syntax for certain functions, which is a 
                                                 
67 The plugin is open source and can be obtained from the repositories indicated in Study II.  
68 Larger steps and interpolation reduce calculation time significantly by reducing the number of calculations, this 
can still be defined manually for increased accuracy with a time tradeoff 
69 Local optimization saves a lot of time, the more the larger the object, but was tricky to implement accurately 
70 Unfavorable base stains will not be optimal and thus calculation of the entire loop can be skipped 
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significant development as Python is notorious for its reliance on indentation71. In essence, this 
will involve adapting PyTMs to the syntax of Python 3 to ensure that it will still work on newer 
versions of PyMOL. The plugin has already been updated with some minor bug fixes and 
additional PTMs and is currently at version 1.2. 
3.2.3.2 Charge and compatibility with other software 
As discussed in Study II the biggest downside is that PyTMs cannot handle charge. This 
inability is largely inherited from PyMOL itself that has very crude handling of chemistry. 
However, the flexibility of PyMOL by its integration of Python allows to either import or 
communicate with 3rd party programs from other sources, e.g. Open Babel [296] or ABPS 
[297]72, and thus outsource certain functionalities to tools better suited for the task. For 
instance, there is an existing plugin called ‘optimize’ for PyMOL using Open Babel to perform 
structural optimizations within PyMOL.  
Accordingly, a future challenge will be to enable compatibility of custom structures with 
services such as GROMACS [298]73, NAMD [299]74 or AMBER[300]75. Certainly this may 
open wider options, e.g. performing molecular dynamics simulation in order to assess the 
conformation of a protein and using force field services such as AMBER to assess surface 
electrostatics. However, this adaptation is entirely new territory76 for myself and adapting 
compatibility will probably require collaboration to integrate parameters from the other ends. 
To give an impression, the cost of developing GROMACS alone is estimated to be 
~27.5 million US dollars with an effort of over 500 person years and ~1.7 million lines of 
code.77 The PyTMs plugin is currently only at 7400 lines of code and less than 2 person years. 
 
3.2.4 CONCLUSIONS AND REFLECTIONS FOR STUDY II 
The PyTMs plugin has been extremely useful for myself and others so far, and I hope that 
development will be continued in some form. However, there are obstacles to overcome if the 
goal is to implement additional functionality directly, or at least to enable the compatibility to 
other services. At this point it is a functional and useful explorative tool, provided the limiting 
caveats are respected. Finally, although the predictive power can be extremely useful in 
generating hypotheses or explaining observations, ultimately experimental data will be 
required to fully confirm them.  
                                                 
71 Indentation is critical for correct parsing in Python and enforces a clean style. However most other languages 
use brackets instead. 
72 http://www.poissonboltzmann.org/ 
73 GROMACS: GROningen MAchine for Chemical Simulations; http://www.gromacs.org/ 
74 NAMD; http://www.ks.uiuc.edu/Research/namd/ 
75 AMBER: Assisted Model Building with Energy Refinement; http://ambermd.org/ 
76 One could do a separate PhD education only on molecular dynamics. 
77 http://www.gromacs.org/About_Gromacs 
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3.3 STUDY III: “NITRATION OF MOG DIMINISHES ITS 
ENCEPHALITOGENICITY DEPENDING ON MHC HAPLOTYPE” 
3.3.1 CONTEXT OF STUDY III 
I was intrigued by the fact that MDA-modified MOG increased proliferation of 2D2 cells and 
demonstrated in Study I that this was attributable to uptake. Importantly I was using PyTMs 
(Study II) to model various scenarios in relation to MDA, among others the presentation of the 
MOG35-55 epitope by the C57BL/6 MHC molecule H2-IA
b. From that it became apparent that 
the C-terminal lysine in MOG35-55 is expendable for the epitope itself as it far outside of the 
MHC groove covered by T cell recognition, but that does not exclude potential peripheral 
interactions. The in vitro data however, does not suggest that there are additional effects on 
antigen presentation, since blocking of uptake reduces the proliferation of 2D2 cell to the same 
levels as MOG (Study I). 
Simultaneously, I was interested in the effect of other modifications on the immunogenicity of 
MOG. For instance, citrullination of MOG was reported to give rise to cross-creative T cells 
and thereby contribute to EAE development [301]. This study notably simply used citrullinated 
MOG35-55 peptides to demonstrate cross-reactivity of peptides being citrullinated at R41 but not 
R46. The molecular modeling supported that conclusion, since the R46 is unlikely to 
accommodate a citrulline at position 46 for appropriate presentation by H2-IAb and/or T cell 
recognition. However, molecular modeling of the MOG protein implies that position 46 is more 
accessible than position 41 (29.7 Å2 solvent-accessible surface area vs. 6.6 Å2). Furthermore, 
the ability of MOG protein to be citrullinated (especially in vivo) is unclear.  
At the same time I had established the nitration modification of MOG with the background that 
protein nitration is a pathological hallmark in MS lesions, but also in conjunction with the C1q 
project (cf. pg. 20). The initial EAE experiments were performed in DBA1 mice because I was 
performing experiments related to mainly Study I and I added nitrated MOG as an additional 
group. These experiments implied that the nitration of MOG would not interfere with its 
antigenicity. However, it was not until I elucidated the impact of nitration in the 3D model of 
the MOG35-55/H2-IA
b complex, and performing experiments in C57BL/6 that the protective 
phenotype became apparent, eventually resulting in Study III. 
 
3.3.2 DISCUSSION OF STUDY III 
Study III combines aspects of both Study I and II, namely by being an intersection of 
biochemistry, immunology and structural bioinformatics. It also is an application example of 
Study II and unlike Study I there is a robust phenotype that the study builds around.  
The immunological implications of antigen nitration in the context of CNS autoimmunity are 
discussed at length in Study II itself. To summarize, nitration is a mechanism through which T 
cell responses to specific epitopes can be silenced in conjunction with a specific MHC 
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haplotype. However, the extent of nitration and its relative contribution to such processes is 
still elusive. 
As not to be redundant of the discussion in the Study itself, in this discussion I will focus more 
on additional aspects. One notion discussed in the Study is that the degree of nitration in vivo 
remains unclear, and that there are distinctions to be made depending on the source and target 
of nitration, as well on the immediate tissue-damaging effects and downstream effects on 
nitrated antigens.  
 
Figure 12 exemplifies that there is abundant nitration within CNS immune infiltrates. Notably, 
this touches upon the notion that macrophages expose their cargo to oxidative burst involving 
iNOS and NOX enzymes, typically to kill pathogens. Thus the extent of nitration within cells 
is possibly modulated by the phagocytosing cell type and its activation state. 
 
 
 
Figure 13: Antibody Ig ELISA from immunized mice 
The ELISA readout is displayed as a heatmap with red color intensity corresponding to the 
indicated scale. Each square represents an average value of multiple sera (n=5) taken at the 
end of EAE experiments. 
MOG35-55 induces significantly weaker, but detectable antibody responses, whereas 
MOG35--5p40NIY is negative. Antibodies react with both MOG and MOG-NIY. MOG-NIY 
immunized mice apparat to have elevated titers toward MOG-NIY, but this may be due to 
additional NIY-specific antibodies. 
Figure 12: Staining of an EAE spinal cord lesion 
for nitrotyrosine 
This image displays an EAE spinal cord lesion with 
infiltrate that has been stained with hematoxylin and 
immunohistochemically for 3-nitrotyrosine (brown 
color). Protein tyrosine nitration is associated to 
inflammation. 
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Additional data that was not included in Study III itself was serum ELISA from immunized 
EAE animal (Figure 13). This data confirms the lack of an immune response towards the 
nitrated APL in C57BL/6 mice. However, there are detectable antibodies towards MOG, even 
in the MOG-NIY immunized group. This possibly reflects that although the dominant T cell 
epitope is absent, activation of B cells still is intact, possibly involving hitherto subdominant 
minor epitopes. These samples were taken at the end of the experiment and therefore most 
likely reflect secondary responses (especially in the case of peptide immunization). Hence it 
would be interesting to follow the dynamics of antibody responses over time, and to observe 
EAE in MOG-NIY immunized mice over longer periods of time. 
 
3.3.3 WHAT ELSE COULD BE DONE? 
Although this would be a larger endeavor and has partly been covered by existing studies of 
pathology, it would be interesting to establish a list of nitrated target proteins in the CNS. We 
currently know that nitration in the CNS and during inflammation occurs, but there is no 
immediate evidence that MOG is actually nitrated (nor citrullinated for that matter). One 
prerequisite would be access to EAE and control tissue, and/or post-mortem lesion and normal-
appearing white matter samples. Secondly, a well-designed proteomics work-flow that would 
enable isolation and analysis of CNS proteins representatively will need be established, 
especially with regards to the lipid rich brain and membrane proteins, and the low abundance 
of target candidates such as MOG. 
This may also involve specifically labeling nitrations with tags [153] in order to maximize the 
chances of detection. In Study III the detection was performed label-free, but including labels 
could further improve the method reliability.  
The effects of antigen nitration by various phagocytes should also be addressed. It would be 
interesting to establish whether specific epitopes become nitrated after uptake, and how the 
activation sate of the phagocytes factors into that. 
An additional aspect of my projects was co-modification, which was never fully explored 
because the effects of individual modifications were not fully established. First, one would 
need to work out standard production routines with retained yield as the order of modifications 
may influence the susceptibility to additional ones (data not included). My prediction is that 
nitration will exert a dominant negative effect over MDA in a 2D2 splenocyte proliferation 
assay, because it denies the dominant epitope. 
Importantly, the non-binding of the nitrated APL should be experimentally confirmed. The lack 
of direct experimental support currently represents a significant drawback in the consistency 
of Study III. Although I originally intended to pursue this, the technical issues discussed in 
Study III currently hamper performing the necessary experiment, I do think they should be 
performed given the chance. Given how central the MOG35-55 epitope and H2-IA
b are to MS 
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research, and the current development in MHC tetramer technology, I am convinced that the 
availability of these tools would be an asset in many aspects. 
It would be interesting to pursue the question concerning the effect of MOG nitration in MHC 
congenic strains and hybrids. My expectation would be that the phenotype of H2q congenic 
C57BL/6 mice might mimic that of H2q DBA1 mice. Conversely, H2b congenic DBA1 mice 
might resemble the C57BL/6 phenotype. Hybrids possibly retain susceptibility, but it would be 
interesting to determine whether the immune response towards nitrated MOG is initiated first 
against the MOG79-98 epitope and then spreads to MOG35-55 from endogenous MOG. 
Lastly, the remaining issue is the clinical translation into MS. As discussed in the study itself, 
there are considerable differences to the heterogeneous epitope responses in MS patients. 
Defining the epitope specificities of MS HLA risk haplotypes has been a challenge in the field. 
Future studies and approaches will hopefully identify defined complexes that will give more 
insight into the autoantigens in MS and their presentation. 
 
3.3.4 CONCLUDING REFLECTIONS ON STUDY III 
Overall this study is a nice example of the applicability of Study II and antigen nitration as a 
mechanism that regulates susceptibility to autoimmune CNS inflammation and dependence on 
genetic background. Although Study III is an independent story, experimental confirmation of 
the lack of binding for the nitrated APL predicted by bioinformatics would be highly desirable. 
Lastly, there are many implications that remain to be explored, as well as related open questions 
that await clarification. 
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3.4 STUDY IV: “RAT BONE MARROW-DERIVED DENDRITIC CELLS 
GENERATED WITH GM-CSF/IL-4 OR FLT3L EXHIBIT 
DISTINCT PHENOTYPICAL AND FUNCTIONAL 
CHARACTERISTICS” 
3.4.1 HISTORIC CONTEXT OF STUDY IV 
The entry point into this study was from a very different angle. My fellow PhD colleague Marie, 
who is the first author, was characterizing these cells in the rat in relation to her projects 
dedicated to deciphering the role of C-type lectins genetically associated to EAE susceptibility. 
My angle was an entirely different one. Based on the prevailing literature at the time, I was still 
hoping to observe strong pro-inflammatory activation of various APCs in response to MOG-
MDA (Study I) and to decipher the mechanism behind it. Having bone-marrow-derived 
dendritic cells (BMDCs) available would greatly enable studying different populations in vitro. 
Secondly, I was questioning the active EAE model with the dilemma that the CFA was 
potentially overriding delicate alterations of immune responses owing to PTMs. A passive 
model of EAE that is based on BMDCs rather than T cells could thus potentially be an option 
to explore and functionally address the role of APCs in EAE. Later it became apparent though 
that classical DCs do not express SRA and thus do not have the capacity to take up MOG-
MDA selectively. Besides we have thus far not succeeded to induce EAE symptoms by transfer 
of antigen-loaded BMDCs. 
3.4.2 DISCUSSION OF STUDY IV 
While I was involved in the project we conducted a series of pilot experiments trying to observe 
immune responses towards antigen after transfer into naïve rats. These experiments were 
largely inconclusive and are not part of Study IV. A major problem is that we failed to observe 
antigen-specific responses78 to either MBP or MOG when assaying the lymph nodes of rats 
following transfer, nor did they develop EAE. We did, however, gather evidence that 
transferred FLT3L BMDCs migrated to lymph nodes. Possibly the use of a foreign as opposed 
to a self-antigen might be an approach. Alternatively, a bystander immunization may be 
required to evoke lasting stimulation. However, several challenges related to cell viability, 
purity and antigen responses still remain. 
A second major obstacle that is discussed in Study IV is the heterogeneity of cell populations 
within the respective protocols, i.e. FLT3L or GM-CSF/IL-4. In retrospect we could have tried 
to account for these differences and/or tried to optimize culture condition to passively select 
homogenous cells. Presently this is still not quite feasible. First it needs to be elucidated which 
additional factors could potentially be applied. The characterized BMDCs as such are 
nonetheless still invaluable tools for in vitro assays.
                                                 
78 The responses were elevated but appeared to respond to culture media. Attempts to culture cells in serum-free 
or rat serum containing media were undertaken but met technical limits. 
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4 CONCLUDING REFLECTIONS AND FUTURE 
PERSPECTIVES 
The projects within this thesis relate to the role of post-translational modifications in CNS 
autoimmunity and inflammation. The overarching aim is to elucidate mechanisms of 
immunology and to improve the understanding of complex processes within diseases such as 
MS, and lastly to identify leads for therapeutic intervention. 
Study I has been at the heart of the project and was a valuable learning experience, although 
overall it did not follow the plan intended for me. The scientific aspects aside, this project was 
defining for my development as a scientist. Personally it highlighted several aspects of 
scientific philosophy: thorough and self-critical methodology yielding conclusive and reliable 
results, critical interpretation of the literature, scientific reading in general to expand the 
horizon and the importance of good project design with either a fail proof hypothesis–
generating approach or a solid phenotype at heart. 
As far as the science is concerned Study I confirms in an elegant way that the lipid peroxidation 
end products of MDA render the carrier protein into a ligand for SRA. The association of SRA 
expression and increased uptake to homeostatic M2-type macrophages is a novel aspect 
implying a more regulated response to MDA adducts that have been demonized in the context 
of autoimmunity. I voiced skepticism towards default pro-inflammatory effects of MDA 
adducts, which I believe are instead attributable to soluble MDA. Dissecting their individual 
effects would be valuable to understanding their impact and risk for autoimmunity, especially 
since lipid peroxidation and MDA adduct formation are not necessarily dissociated in vivo. 
Understanding these mechanisms and their individual impact on immunology will be critical 
to draw a more diversified picture of the role of PTMs in autoimmunity. 
Study II and the development of the PyTMs plugin had its roots in the infeasibility of pursuing 
crystallization of MOG-MDA. However, although initially being a side-track, I believe that 
due to the considerable investments that were made in its development, the plugin can 
potnetially contribute more to the research of PTMs in the long run. There are some limiting 
caveats and challenges associated to its future development, however, this could be a slowly 
evolving project that will require collaboration.  
Notably, Study III is already an application example of the PyTMs plugin allowing me to 
address research questions and to explain experimental observations at a molecular level. The 
design of this project was significantly more straightforward and based on a clear phenotype 
that facilitated the process. Although experimental validation for the conclusion that 
presentation by H2-IAb is indeed denied is pending, I consider the likelihood of confirmation 
is theoretically well supported. Nonetheless, I fully agree with the notion that experimental 
evidence would significantly bolster the conclusion and tie up the story. Apart from that, having 
H2-IAb complexes available for other assays (e.g. tetramer staining of MOG35-55 reactive T 
cells) would be invaluable tools for other projects. 
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The observation that nitration diminishes immune responses to specific epitopes depending on 
the MHC background is extremely intriguing in the context of risk haplotypes and genetic 
predisposition, but also has implications on the dynamics of immune responses. Additional 
examples and the relative contribution to shaping immune response in vivo remain to be 
investigated. 
Although from its content Study IV is not immediately connected to the theme of PTMs the 
intent with participation from my side was to develop new methods and tools to address 
immunological questions related to modified antigen. Similar to Study II, Study IV is indicative 
of a quest for new techniques and tools to enable scientists to address questions with a novel 
approach. Eventually the application of new technologies is a key factor driving scientific 
progress. Our thorough characterization in Study IV reflects that establishing, optimizing and 
defining methods and tools is something that it integral to scientific progress.  
This thesis is very diverse in the ground that it covers. I have built up many aspects of the 
projects from scratch, starting from bacteria to produce my own protein material, chemical 
modification and fluorescent labeling, biochemical analyses and mass spectrometry all the way 
to in vivo applications. This was paralleled by bioinformatics approaches, molecular modeling 
and modern data analyses. Altogether these provide a valuable skill set for quality science. 
 
In summary, the studies and this thesis provide both tools and more diversified interpretations 
in the context of post-translational modifications in autoimmunity, particularly for myelin 
oligodendrocyte glycoprotein and CNS autoimmunity. The interactions in immunology are 
extremely complex. Thus every individual study represents a small piece of a gigantic evolving 
puzzle that is just beginning to outline a fascinating and enigmatic picture that we cannot begin 
to fully grasp quite yet. 
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Marc, Ralf & Frank: die wilden Jahre sind glücklicherweise lange vorbei  Jetzt da wir alle 
erwachsen sind ist es toll, dass wir uns alle so gut verstehen! 
Alina & Rosa: Ihr seid beide so herzliche Menschen und es freut mich wie ihr die Familie 
ergänzt. 
 
 
Sara. Jag vet inte hur jag skulle kunna tacka dig för all ditt stöd. Jag skulle nog inte ha klarat 
mig om det inte ha varit för din skull. Nära dig är jag mig själv och du kallar fram det bästa i 
mig. Jag älskar dig och alla skratten vi delar. 
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